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Abstract 
 
The purpose of this work was to assess the value of humoral and genetic risk markers in the 
prediction of type 1 diabetes in siblings of children with type 1 diabetes, to characterise preclinical 
course of beta-cell autoimmunity in siblings, and to investigate the frequency of autoantibodies and 
their relations to genetic markers, beta-cell function and progression to type 1 diabetes in a 
schoolchild population. 
The prevalence and predictive value of autoantibodies was studied in 755 initially unaffected 
siblings, and the combination of genetic markers and autoantibodies in 701 of these siblings. Islet 
cell autoantibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase antibodies 
(GADA) and IA-2 antibodies (IA-2A) were all shown to be of value in the prediction of type 1 
diabetes in siblings initially tested at or close to the diagnosis of type 1 diabetes in the index case in 
the family. The risk of progression to type 1 diabetes was related to the number of autoantibodies 
detected, and the PPV of multiple autoantibodies was 55% over a period of 8 years. Autoantibodies 
were closely associated with HLA risk markers. A combination of the genetic markers and 
autoantibodies increased the PPVs of all autoantibodies substantially but also markedly reduced the 
sensitivity.  
The preclinical course of type 1 diabetes was investigated in 39 initially unaffected siblings who 
progressed to clinical disease during the follow-up. These individuals were characterised by the 
high-risk genetic markers, decreased beta-cell function and humoral autoimmunity against multiple 
beta-cell targets. However, all measures implied a remarkable individual variation in the rate of the 
disease process and the pattern of humoral beta-cell autoimmunity. Furthermore, the autoimmune 
process resulting in clinical presentation of type 1 diabetes could not be unambiguously 
distinguished from autoimmunity not leading to clinical disease within almost 10 years of follow-
up. 
The frequencies of ICA, IA-2A, GADA and IAA in 3652 healthy Finnish schoolchildren were 
2.8%, 0.6%, 0.5% and 0.9%, respectively, and multiple antibodies were detected in 0.6% of these 
children. GADA and multiple antibodies were related to the DQB1*0302 allele and the 
DQB1*02/0302 genotype. A reduced first-phase insulin reponse (FPIR) was associated with IA-
2A, GADA, IAA and multiple antibodies, but not with ICA or any specific DQB1 allele or 
genotype. Four subjects progressed to type 1 diabetes, all of them having multiple autoantibodies 
and those two who underwent an intravenous glucose tolerance test had also a reduced FPIR. None 
of the progressors carried the high risk DQB1*0302 allele and two of them even carried the 
protective DQB1*0602 or *0603 allele. 
In conclusion, autoantibodies alone are recommended as first-line screening in siblings, whereas 
subsequent determination of HLA-DQB1 markers and their combination with autoantibodies 
provides a valuable tool for more precise risk assessment. Wide heterogeneity in the course of 
preclinical type 1 diabetes complicates an accurate estimation of the individual risk of progression 
to type 1 diabetes among siblings of children with type 1 diabetes. Combined screening for 
autoantibodies is recommended for the assessment of the risk of progression to type 1 diabetes in 
schoolchild populations, whereas the present observations challenge the value of current genetic 
risk markers in predictive strategies targeting schoolchildren. 
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Type 1 diabetes is one of the most common chronic disorders among children and 
adolescents in the industrialised countries. It is characterised by a life-long absolute need 
for exogenous insulin due to destruction of the insulin-producing pancreatic beta cells. As 
a incurable chronic disease, it has many life-threatening implications for the affected 
subjects. The daily subcutaneous injections of insulin, the strict control that has to be 
maintained over diet and exercise, and the awareness of the potential severe long-term 
complications can seriously disturb normal mental and social development. The disease 
also places an extra burden on the parents, siblings and children of the affected 
individual. In addition, the insulin treatment, calls for regular monitoring by health care 
professionals and management of the long-term complications results in substantial costs 
to the whole of society. For reasons that are as yet unknown, the incidence of this severe 
disease has been constantly increasing in the developed countries during recent decades 
(1), and that recorded in Finland is the highest in the world (2). 
Despite extensive research, the pathomechanism(s) underlying type 1 diabetes have 
remained unresolved and the course of the autoimmune destruction process in the 
pancreas during the prodromal period is inadequately characterised. Whether this process 
always leads to clinical manifestation of the disease, and whether this process is similar 
in all individuals (e.g. in first-degree relatives and in the general population) is unclear. 
Adequate characterisation of the molecular mechanisms and pathophysiological course of 
beta-cell autoimmunity is also a prerequisite for the development of effective preventive 
strategies. Furthermore, although the pathomechanism of type 1 diabetes might be 
resolved and a method developed for preventing the disease, the risk individuals will 
always have to be identified, unless the intervention can be implemented to target the 
whole population. Thus, both research into the preclinical phase of beta-cell destruction 
and research into potential predictive strategies for use with risk individuals and in the 
general population are important.  2.  Review of the literature 
2.1. Diabetes mellitus 
Diabetes mellitus covers a group of metabolic diseases characterised by hyperglycaemia. 
This pathophysiological condition results from defects in the secretion and/or action of 
insulin. According to a recent report by an expert committee appointed by the American 
Diabetes Association, diabetes mellitus can be classified into four major 
aetiopathogenetic categories: type 1 diabetes, type 2 diabetes, other specific types and 
gestational diabetes mellitus (3). The vast majority of cases of diabetes fall into the first 
two categories. 
2.1.1. Pathophysiology of type 1 diabetes 
The cause of hyperglycaemia in type 1 diabetes is an absolute deficiency in insulin 
secretion due to autoimmune destruction of the insulin-producing beta cells. The 
connection between the pancreas and diabetes was first discovered at the end of 19
th 
century, when von Mering and Minkowski observed that removal of the pancreas caused 
diabetes-like symptoms in a dog (4). Research carried out at the beginning of 20
th century 
revealed fibrosis, hyalinosis, atrophy, and infiltration of inflammatory cells in the 
pancreatic islets of patients with recent-onset diabetes (5-7). The presence of 
inflammatory cells in the islets of Langerhans was later termed "insulitis" (8). The 
fundamental work underlining the possible involvement of the immune system in the 
development of type 1 diabetes was done by Gepts (9). He studied in detail the 
significance of insulitis at the clinical onset of diabetes, and used new quantitative 
methods to estimate the loss of insulin-producing cells in such patients. He observed 
insulitis in 16 of 23 subjects with diabetes who died within 6 months of diagnosis, while 
it was rarely seen in patients who lived for more than one year. Immunocytochemical 
studies have later shown that insulitis occurs only in islets containing beta cells, and after 17 
the destruction of the beta cells the atrophic islets secrete various other hormones, but not 
insulin (see 10). 
The large reserve capacity of the endocrine pancreas maintains sufficient insulin 
production and normoglycaemia until 80-90% of the functioning beta cells have been 
destroyed. Then the disease progresses to clinical manifestation, and the symptoms of 
hyperglycaemia appear. These include thirst, ample drinking, polyuria and weight loss. 
The clinical onset of the disease is usually acute, leading rapidly to ketosis and 
ketoacidosis. If exogenous insulin therapy is not started, the condition will progress to 
coma and death of the patient. Carbohydrate metabolism is restored shortly after insulin 
therapy has been started. Thereafter the patients are dependent on exogenous insulin for 
the rest of their lives. 
2.2. Epidemiology of type 1 diabetes 
Epidemiological data have revealed a considerable geographical variation in the 
worldwide incidence of type 1 diabetes. The report of the WHO DIAMOND project on 
worldwide incidence rates, compiled in the late 1980's, showed that the lowest incidence 
was observed in Asia, followed by Oceania (Australia and New Zealand) and South and 
North America, with the highest rates in Europe (11). Few data were available from 
Africa. A substantial country-to-country variation was also observed within the same 
continent, with the highest variation being in Europe. In general, the incidence in 
Northern Europe was higher than that in other parts of Europe, with the exception of 
Sardinia in the south (12) and Iceland in the north (13).  
The highest incidence of type 1 diabetes in the world has been reported in Finland 
during the last twenty years (11, 14-16), and the figure has been gradually increasing (2). 
Where the incidence in the first nationwide study in 1953 was reported to be 12 per 
100,000 (17), it was 36 per 100,000 by the end of the 1980's (18). The incidence 
remained fairly stable from 1987 to 1992, leading to speculations of a possible levelling 
off in the increase in incidence. The incidence has, however, further increased since 1992, 
reaching 40 per 100,000 in 1994, 45 per 100,000 in 1996 (2) and a record of 50 per 
100,000 in 1998 (Reunanen, A., personal communication). Accordingly, the incidence 
rate is about four times higher than it was 45 years ago. Similar increases in incidence 
have also been reported in other populations (19-25). The factors underlying this trend 
have so far remained only speculative, potential candidates being genetic factors, diet and 
viral infections.  
2.3. Aetiology of type 1 diabetes 
Although the aetiology of type 1 diabetes is still open, there is strong evidence that both 
genetic factors and the environment contribute to the pathogenetic process. A variety of 
genes have been shown to be associated with it, the most important being HLA and the 18 
insulin gene region. Potential environmental factors include viral infections and dietary 
constituents.  
2.3.1. Genetic susceptibility 
The first evidence for an association between certain genes and type 1 diabetes was found 
in 1973 and 1974, when the frequency of the HLA class I alleles B8 and B15 was 
reported to be higher in patients with type 1 diabetes than in control subjects (26, 27). 
The genetic linkage between the HLA region and type 1 diabetes was soon confirmed in 
family studies (28). The observation that the disease occurs more frequently in relatives 
of patients with type 1 diabetes than in the general population provided further evidence 
for the involvement of genetic factors in susceptibility (29). Later studies have shown the 
HLA region to be the major genetic determinant of susceptibility to type 1 diabetes. 
Although several hypotheses have been put forward (e.g. 30, 31), the exact mechanism of 
the involvement of the HLA genes in beta-cell destruction remains unclear. 
2.3.1.1. The HLA (Human Leucocyte Antigen) region 
HLA is a segment of approximately 3500 kb on chromosome 6p21. It contains a variety 
of genes, most of which are involved in the function and regulation of immune responses. 
The denomination of these genes is shown in Fig. 1. The class I genes encode 
glycoproteins expressed on the cell surface of most nucleated cells, whereas the class II 
genes encode heterodimeric proteins expressed on the surface of antigen-presenting cells 
(e.g. dendritic cells, macrophages and lymphocytes). The genes in the class III region 
encode products with a variety of functions, including complement components, tumor 
necrosis factors and the enzyme 21-hydroxylase. Some other genes (e.g. TAP genes) have 
also been mapped within the HLA region (32). The most striking characteristic of the 
genes in the HLA region is their high degree of polymorphism, expressing pronounced 
linkage disequilibrium between certain alleles. This means that some alleles occur 
together more often than might be expected from their gene frequencies. Certain 
extended haplotypes are therefore often maintained in populations. 
Since the fundamental observation of a linkage between HLA genes and type 1 
diabetes (26, 27), intensive research has continued, aimed at further characterization of 
this phenomenon. In the late 1970's a close association was demonstrated between HLA 
class II gene products and type 1 diabetes (33, 34), and a primary role was suggested for 
the HLA-D genes in susceptibility to the disease (35, 36).  19 
 
Fig. 1. Map of the HLA region on the human chromosome 6p21. 
 
 
More than 90% of the patients with type 1 diabetes in Caucasian populations have 
been shown to carry the HLA-DR3 and/or DR4 allele, as opposed to 40-50% of healthy 
subjects. The highest risk is associated with the heterozygous DR3/4 phenotype, the 
frequency of which is 30-50% in patients but only 1-6% among healthy controls (37, 38). 
In contrast, the presence of the DR2 allele has consistently been reported to be associated 
with a particularly low risk of type 1 diabetes (37, 39). Further methodological 
developments in molecular biology made it possible to examine the associations at the 
DNA level. Based on these new methods, DQB1 was further subdivided into 
DQB1*0301 (DQ7) and DQB1*0302 (DQ8) alleles, the former being negatively and the 
latter positively associated with susceptibility to type 1 diabetes (40-44). Similarly, DR4 
was further divided into subgroups, so that only the subtypes Dw4 and Dw10 were shown 
to be associated with the increased disease susceptibility (30). In addition, the lower 
susceptibility attributed to the DR2 allele was shown to be associated only with the DR2-
DQB1*0602 haplotype, but not with the other DR2 haplotypes (45). These observations 
indicated that the DR and DQ loci are linked to each other, and that the primary 
susceptibility resides rather in the HLA-DQ than in HLA-DR region. Many studies have 
thereafter confirmed the close association between certain HLA-DQB1 alleles and type 1 
diabetes. The DQB1*0302 and/or DQB1*02 alleles are found in 90-95% of patients with 
the disease (46, 47). The genotype most closely associated with the disease has proved to 
be DQB1*02/0302, which is found in 25-44% of patients but in less than 6% of control 
subjects (47-53).  
2.3.1.2. Other susceptibility genes 
Another major genetic determinant of susceptibility to type 1 diabetes has been 
discovered in chromosome 11p15, which contains the insulin gene region. The first 
reports in the early 1980's were inconclusive due to the relatively small populations 
analysed (54-56). As a result of the high frequency of class I (disease-associated) alleles 
in the general population, conclusive evidence for the linkage between the insulin gene 
region and type 1 diabetes was not obtained until 1991 and 1992 (57, 58). The actual 
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susceptibility locus seems to be restricted to the VNTR (variable number of tandem 
repeats) minisatellite region, 596 basepairs upstream of the insulin gene (59-62). There 
are three classes of VNTR alleles, of which class I predispose the subject to type 1 
diabetes, while the class III alleles have a predominantly protective effect (57, 59-61, 63). 
The mechanism by which the insulin gene region contributes to the disease process is 
thought to be related to the level of insulin expression (61, 62, 64). 
In addition to HLA and the insulin gene region, at least 18 other chromosome regions 
have been linked to type 1 diabetes, although statistically significant evidence for such 
linkage has been presented only for 10 of these (65).  
2.3.2. Environmental factors 
Studies on identical twins provide the most convincing evidence for the importance of 
environmental factors in the pathogenesis of type 1 diabetes. The concordance rate for 
type 1 diabetes in identical twins is only 13-50% (66-70). In addition, it has been 
observed that only a minority of individuals with high risk genotypes progress to clinical 
disease. The most likely environmental factors contributing to the aetiopathogenesis of 
type 1 diabetes include infectious agents and dietary factors. These could operate by 
initiating or accelerating beta-cell autoimmunity. 
2.3.2.1. Viral infections 
The first observations concerning viruses and type 1 diabetes were made in 1864 by 
Stang, who described a patient with diabetes after chickenpox (71), and in 1899 by Harris 
who described a patient who presented with diabetes shortly after mumps infection (72). 
Thereafter, various viruses have been implicated in the aetiology of diabetes. Congenital 
rubella infection has been shown to be closely associated with progression to type 1 
diabetes (73-75). A case report of an infant with subsequent diabetes after congenital 
cytomegalovirus (CMV) infection (76), the demonstration of the CMV genome in a 
patient with recently diagnosed type 1 diabetes (77), and a detection of an association 
between islet cell antibodies and CMV antibodies have all suggested a connection 
between CMV and type 1 diabetes (78, 79). However, no evidence for this association 
was observed in a prospective follow-up study on siblings of children with type 1 
diabetes (80). Evidence for a temporal association between Epstein-Barr virus (EBV) 
infections and type 1 diabetes, and a decreased immune response to this virus have been 
reported (81). Endogenous retroviruses have also been implicated as potential 
aetiological factors for type 1 diabetes (82). 
The most convincing evidence has accumulated for enteroviruses. Gamble et al., in 
1973, reported a higher frequency of antibodies to Coxsackie B4 virus in patients with 
diabetes than in controls (83). The isolation of the Coxsackie B4 virus from the pancreas 
of a child with acute onset diabetes further supported the role of enteroviruses in the 21 
pathogenesis of this disease (84). Thereafter, there were several reports of higher 
frequencies of antibodies to various enterovirus serotypes in subjects with type 1 diabetes 
than in controls (85-94). In a prospective Finnish study, serologically documented 
enterovirus infections were shown to be more common in siblings who developed type 1 
diabetes than in those who did not (94). The appearance of islet cell antibodies (ICA) 
reflecting beta-cell autoimmunity was also shown to be temporally associated with 
enterovirus infections (95), and several enterovirus serotypes were associated with 
prediabetic autoimmune episodes (96). Caution should be exercised, however, when 
interpreting results suggesting a potential role for enteroviral infections in the 
pathogenesis of type 1 diabetes. First of all, the presence of antibodies against 
enteroviruses at the time of disease onset or in subjects with signs of autoimmunity does 
not necessarily prove causality (97). So far there are only two studies that have 
demonstrated an increased frequency of enterovirus RNA in sera of patients with type 1 
diabetes relative to controls (98, 99). Furthermore, due to particular HLA genotypes, 
prediabetic and diabetic subjects may have a stronger humoral response to enterovirus 
infections, they might be more prone to enteroviral infections, or they may be in a non-
specific hyperimmune state, as suggested by Graves et al. (97). 
Several mechanisms have been proposed for viruses in initiating or triggering beta-cell 
autoimmunity. In the molecular mimicry model, a viral protein and a beta-cell protein are 
assumed to share a common amino acid sequence (100, 101). An immune response to this 
viral protein could result in the appearance of antiviral cytotoxic lymphocytes that react 
with the self-protein on the beta cell (100). Alternatively, a beta-cell trophic virus may 
generate cytokines and other inflammatory mediators that induce the expression of 
adhesion molecules in the vascular endothelium of the pancreatic islets. This activation 
would result in increased adhesion and extravasation of circulating leukocytes and the 
presentation of beta-cell antigens from the damaged beta cells to lymphocytes by 
infiltrating macrophages (100). Other potential mechanisms have also been suggested 
(see 97, 102, 103). 
2.3.2.2. Dietary factors 
Dietary factors have for a long time been connected with the aetiology of type 1 diabetes, 
on evidence coming from both animal and human studies. Several food components have 
been suggested as putative dietary risk factors, the most important being cow’s milk 
proteins (104).  
The observation that a lack of breast-feeding predisposed subjects to diabetes (105), 
and the finding that milk powder induced diabetes in BioBreeding rats (106), were the 
first clues to a link between milk and type 1 diabetes. Furthermore, the observation of an 
increased frequency of IgG antibodies against BSA (bovine serum albumin) in patients 
with newly diagnosed type 1 diabetes and the description of a homology region between 
BSA and islet cell antigen 69 (ICA69) (107) led to the hypothesis that type 1 diabetes 
might be induced by milk protein (108). This milk hypothesis suggests that early 
exposure to cow's milk protein may trigger type 1 diabetes. Controversial results have 22 
been published since, however. The main evidence for this hypothesis is retrospective and 
indirect, based on several case-control studies on breast-feeding and progression to type 1 
diabetes (109). On the other hand, several studies have failed to show any association 
between the duration of breast-feeding or time of cow's milk exposure and progression to 
diabetes (e.g. 110). Thus the data concerning the milk hypothesis are controversial. The 
only way to demonstrate conclusively whether cow's milk has an important role in the 
aetiopathogenesis of type 1 diabetes or not, is a prospective, double-blind, randomised 
intervention trial. Such an international multi-centre study is now in its planning phase 
(111). Cow’s milk formula feeding has recently been shown to induce a humoral immune 
response to bovine insulin, and these antibodies cross-react with human insulin (112). 
Accordingly, dietary bovine insulin has been suggested as an environmental trigger of 
primary immunisation to insulin. Such an immunisation could in a few unfortunate 
individuals lead to an autoaggressive immune response to human insulin and thereby 
explain the epidemiological link between the risk of type 1 diabetes and early exposure to 
cow’s milk formulas. 
2.3.2.3. Other factors 
Chemical toxins can cause type 1 diabetes by a variety of mechanisms (see 113). These 
include direct cytotoxicity to the beta cells, and indirect autoimmune mechanisms. 
Alloxan and streptozotocin are the classical toxins inducing diabetes in rodents (e.g. 114). 
In 1981 smoked and cured mutton, which contains considerable amounts of N-nitroso 
compounds, was proposed as an aetiological factor for human type 1 diabetes (115). 
Contradictory results were reported later (116), and the association still needs to be 
confirmed. The rodenticide Vacor, N3-pyridylmethyl-N'p-nitrophenylurea, has been 
reported to have caused more than 30 cases of diabetes in the USA and more than 250 in 
Korea (see 113). 
Kolb and Elliot have suggested that the increase in the incidence of type 1 diabetes 
may be due to an improvement of hygienic conditions and reduced postnatal exposure to 
microbial antigens (117). However, no direct evidence of any link between hygienic 
conditions and human type 1 diabetes has been reported. The possible role of 
vaccinations (118-120), average temperature (121-123) and psychosocial factors (124, 
125) in the aetiology of type 1 diabetes has also been discussed. 
2.4. Pathogenesis of type 1 diabetes 
Type 1 diabetes has proved to be an immune-mediated disease. Evidence for this includes 
the presence of inflammation in the pancreatic islets at the time of disease onset (9), the 
association between the disease and immunoregulatory genes (26, 33), the presence of 
humoral and cellular autoimmunity against beta-cell structures (126-128), the association 
of the disease with other autoimmune disorders (129), the ameliorating effect of 23 
immunosuppressive agents on the disease process (130, 131), and the reappearance of 
diabetes and beta-cell autoimmunity after pancreatic transplantations (132, 133).  
Several hypotheses have been introduced in order to explain the immunological 
pathomechanism(s) underlying type 1 diabetes (134). The key event in selective beta-cell 
destruction seems to be the infiltration of the islets by T lymphocytes and the recognition 
of beta-cell antigens by such cells. Macrophages and B-lymphocytes are also present 
(135-138). The nature of the initial event triggering beta-cell autoimmunity is unclear, 
however, and it is not known whether there is one primary autoantigen initiating the 
disease process or whether various autoantigens act in concert. Nor is it clear whether 
beta-cell autoimmunity originates from the activation of multiple autoreactive T-cell 
clones or whether there is a single clone directed against one primary autoantigen.  
2.4.1. Targets of humoral and cellular autoimmunity 
One of the most evident signs of beta-cell autoimmunity is the presence of circulating 
autoantibodies against a variety of beta-cell structures. The actual significance of 
autoantibodies in the pathogenesis of type 1 diabetes is still unresolved, but they can 
certainly be used as markers of ongoing beta-cell autoimmunity. In addition, the target 
antigens of autoantibodies are most probably also those of autoreactive T cells. During 
the last decade, several specific beta-cell autoantigens have been characterised using sera 
from patients with type 1 diabetes (Table 1). 
 
 
Table 1. List of potential beta-cell autoantigens in type 1 diabetes. 
_______________________________________________________________________ 
 
A n t i g e n          R e f e r e n c e  
________________________________________________________________________ 
Insulin         159 
GAD         183 
IA-2/ICA512        214-216 
IA-2β         222,  223 
GLIMA         237 
ICA69         238 
38  kDa  jun-B        243 
Carboxypeptidase  H  (CPH)      244 
Heat  shock  protein  (HSP)       245 
Aromatic L-amino acid decarboxylase (AADC)      246 
DNA  topoisomerase  II       247 
Imogen  38        250 
Bile  salt-dependent  lipase  (BSDL)      251 
______________________________________________________________________ 
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2.4.1.1. Islet cell antibodies (ICA) 
The presence of islet cell antibodies (ICA) reacting with cytoplasmic structures of all 
endocrine cells within the pancreatic islets was initially reported in patients with type 1 
diabetes and polyendocrine deficiencies (126). ICA are detectable by an indirect 
immunofluorescence technique on frozen sections of human pancreas, and have been 
observed in 60-90% of patients with newly diagnosed type 1 diabetes (33, 139-150). 
Immunofluorescence staining of ICA has proved to be directed against a variety of 
antigenic targets, the two major antigens being the enzyme glutamic acid decarboxylase 
(GAD) and the IA-2 (ICA512) protein (151-155).  
2.4.1.1. Insulin 
Insulin is an important autoantigen in type 1 diabetes. It is the only beta-cell specific 
antigen identified so far, and thus a logical candidate to be a primary autoantigen (156). 
Antibodies against insulin were first described in 1963 (157) and autoimmunity against 
insulin in 1970 (158). It was not until 1983, however, that Palmer and colleagues 
carefully documented insulin autoantibodies (IAA) in 18% of newly diagnosed patients 
with type 1 diabetes before the start of insulin treatment (159). The prevalence of IAA in 
patients at the time of diagnosis has later been reported to be 30-50% (145, 150, 160-
168). A relation between IAA and certain HLA susceptibility alleles has been reported in 
patients with newly diagnosed type 1 diabetes (167, 169). 
Cellular autoimmunity against insulin was first described in 1975 (170). Thereafter, 
proliferative T-cell responses against insulin have been reported both in patients with 
type 1 diabetes and in healthy individuals (128, 171, 172). A recent international T-cell 
workshop showed, however, that the methodology used for the detection of proliferative 
T-cell responses to any antigen is problematic and results in major differences between 
laboratories and controversial results (173). Proinsulin, the precursor of insulin, has also 
been suggested as a candidate autoantigen in type 1 diabetes, since autoantibodies and 
proliferative T-cell responses against this protein have been observed (174-179). The 
roles of insulin and proinsulin in the pathogenesis of type 1 diabetes nevertheless still 
remain to be defined. 
2.4.1.2. Glutamic acid decarboxylase (GAD) 
In 1982, Baekkeskov et al.  reported that sera from patients with type 1 diabetes were 
able to immunoprecipitate proteins from human islets of Langerhans metabolically 
labelled with 
35S-methionine (127). In their experiments a 38kD protein and a 64kD 
protein were specifically immunoprecipitated by diabetic sera. Subsequently, close to 
80% of patients were shown to have autoantibodies against the 64kD protein at the time 
of diagnosis (180-182).  25 
In 1990, the 64kD protein was identified as the enzyme glutamic acid decarboxylase 
(GAD) (183). This belongs to the family of pyridoxal-5-phosphate (PLP) dependent 
decarboxylases (184) and catalyses the conversion of L-glutamate to γ-amino butyric acid 
(GABA), which is the major inhibitory neurotransmitter in the brain (see 185). GAD 
exists in two isoforms, GAD65 and GAD67, encoded by different genes (186). Outside the 
nervous system, GAD has been detected in several tissues, including the adrenal glands, 
duodenum, fallopian tubes, gall bladder, muscle, pancreas, stomach, thyroid gland, 
thymus and testis (see 187). However, the amount expressed is comparable to that in the 
nervous tissue only in the pancreatic islets, fallopian tubes and testis. Only GAD65 is 
expressed in the human pancreatic islets and it is localized particularly in the beta cells, 
but the enzyme can also be detected at low concentrations in alpha cells (188). The role 
and function of GAD and the GABA-ergic system in the islets is unclear, although a 
paracrine role for GABA has been implicated (189). 
GAD65 is the major GAD isoform associated with type 1 diabetes (190-193). The 
reported frequencies of autoantibodies against it (GADA) in recent-onset cases vary from 
60 to 85% (149, 167, 194-199). GADA have been shown to be related to HLA risk 
markers, since an increased frequency has been observed in patients with the HLA-
DR3/4 phenotype (197, 200), and especially in those carrying the HLA-DQB1*02 allele 
(167, 169).  
After the identification of GAD65 as an autoantigen in type 1 diabetes, a proliferative 
T-cell response against this protein was shown to be present in close to 50% of newly 
diagnosed patients and in less than 10% of healthy control subjects (201). There were 
then several reports of autoreactive T-cells against GAD65 or GAD65-derived synthetic 
peptides in patients with type 1 diabetes (177, 202-208). Two studies suggesting a 
primary role for GAD in the induction of beta-cell autoimmunity in non-obese diabetic 
(NOD) mice were published in 1993 (209, 210). These provided evidence that a loss of 
tolerance to GAD65 is an early and necessary step in the pathogenesis of type 1 diabetes 
in this animal model. They showed that a T-cell response to GAD develops at an early 
stage, and occurs at the same time as the onset of insulitis, and before T-cell responses 
arise to a variety of other autoantigens. Antibodies against GAD also appeared at the 
same time. These studies also showed that intravenous and intrathymic injections of 
GAD65 markedly reduced T-cell responses to GAD and other autoantigens, and prevented 
insulitis and diabetes in these mice, indicating GAD65-induced tolerance. Later, GAD65-
specific CD4
+ regulatory T-cells were shown to have a critical role in the suppression of 
the diabetogenic response in the NOD mouse (211). By contrast, intrathymic injections of 
two GAD65 peptides or GAD purified from rat brain were shown to accelerate the 
diabetogenic process and induce diabetes (212, 213). Whether these observations are 
applicable to man, and whether GAD has a primary role in human type 1 diabetes is still 
not clearly established.  26 
2.4.1.3. Insulinoma-associated protein 2 (IA-2) 
Screening of a human islet cDNA expression library and a human insulinoma library led 
to the identification of insulinoma-associated protein 2 (IA-2), which was shown to be 
another major autoantigen involved in type 1 diabetes (214-216). IA-2 is a 979-amino-
acid transmembrane protein with structural similarities to the members of the protein 
tyrosine phosphatase (PTP) family (217, 218), and it is encoded by a gene located on 
chromosome 2q35 (219). IA-2 is predominantly expressed in neuroendocrine cells, 
including pancreatic islets and brain cells (215, 220, 221). Another PTP-related protein, 
IA-2β, was also isolated, showing substantial similarity to IA-2 (222, 223). The specific 
function of these PTP proteins remain unclear (224, 225). 
The IA-2 protein is a major target of autoantibodies in type 1 diabetes. The presence of 
these antibodies (IA-2A) has been demonstrated in 50-85% of patients (149, 221, 226-
232), and significant association has been reported between IA-2A and the HLA-DR4 
allele (233) and the HLA-DQB1*0302 allele (169, 229). Together with GADA, IA-2A 
represents a major constituent of the immunofluorescence reactivity of ICA (155), and it 
has been suggested that combined detection of IA-2A and GADA could replace the 
relatively laborious procedure of histochemical ICA testing (227, 230). 
Cellular immune responses to IA-2 have also been reported (234, 235). Ellis et al. 
demonstrated a proliferative T-cell response to IA-2 in 42% of patients with type 1 
diabetes as compared with 8% of healthy control individuals, supporting the 
autoantigenic nature of IA-2 in type 1 diabetes (235). Similar results have been reported 
by other groups later (177, 236). 
2.4.1.4. Other antigens 
Several other proteins have been cloned and implicated as candidate autoantigens in type 
1 diabetes (Table 1), but their significance remains unclear and has not yet been 
confirmed. The 38-kD autoantigen GLIMA is an amphiphilic membrane glycoprotein 
specifically expressed in islet and neuronal cell lines (237). Like GADA, IA-2A and IAA, 
autoantibodies to GLIMA have been detected by liquid phase immunoprecipitation 
assays. These are reported to be present in close to 20% of patients with type 1 diabetes, 
and were suggested to represent the "missing" proportion of ICA staining, thus 
complementing GADA and IA-2A (237). Screening of a human islet cDNA expression 
library with ICA-positive sera revealed a 69 kD autoantigen (ICA69) (238). Partial 
sequence homology was observed with bovine serum albumin (BSA), which had earlier 
been suggested to trigger type 1 diabetes (107). The expression of ICA69 showed no 
tissue specificity (239), however, and controversial results have later been obtained 
regarding ICA69 as an autoantigen in type 1 diabetes (149, 240-242). Other autoantigens 
that have been cloned and implicated in type 1 diabetes include the nuclear transcription 
protein 38K-jun-B (243), carboxypeptidase H (CPH) (244), heat shock proteins (HSP) 
(245), aromatic L-amino acid decarboxylase (AADC) (246), DNA topoisomerase II 
(247), glycolipids (248, 249) and Imogen 38 (250). Most recently, bile salt-dependent 27 
lipase (BSDL) originating from the exocrine pancreas was reported to be a potential 
autoantigen in type 1 diabetes (251). Antibodies against this enzyme were observed in 
more than 70% of patients with type 1 diabetes but only 8% of the healthy controls. The 
authors thus suggested that in addition to pancreatic beta cells, acinar cells may also be 
affected in type 1 diabetes. 
2.4.3. Temporal course of beta-cell autoimmunity 
Although the slowly progressive nature of autoimmune beta-cell destruction has been 
known for more than two decades, there is still no consensus regarding its pattern and 
course. Autoantibodies and signs of deteriorating beta-cell function can be detectable 
years before the clinical manifestation of the disease. Some studies indicate a linear 
decline in beta-cell mass (252), whereas others suggest less predictable non-linear beta-
cell destruction with fluctuations in immunological and metabolic abnormalities (253-
255). 
In 1984, Srikanta and colleagues studied the timecourse of beta-cell function in nine 
subjects before the manifestation of clinical type 1 diabetes (252). They observed a 
progressive loss of the first-phase insulin response to intravenous glucose, indicating a 
linear loss of beta-cell function during the preclinical period. Based on these 
observations, they suggested that the time to onset of type 1 diabetes would be 
predictable. Further studies in ICA-positive first-degree relatives indicated a strong 
association between IAA levels and age at the clinical onset of type 1 diabetes, resulting 
in the suggestion that IAA might reflect the rate of beta-cell destruction (256, 257). A 
dual-parameter model based on the first-phase insulin response to intravenous glucose 
and the IAA level was presented for predicting the time to the onset of diabetes (258, 
259). 
In the Seattle Family Study, nine ICA-positive and 10 ICA-negative first-degree 
relatives of patients with type 1 diabetes were evaluated prospectively for beta-cell 
function, autoantibodies and progression to the clinical disease (260). Five subjects were 
persistently positive for ICA, and three of them had stable beta-cell function without 
progression to clinical disease. In addition, five subjects had fluctuating levels of ICA 
and no signs of deteriorating beta-cell function. The authors suggested that intact beta-
cell function and fluctuating ICA status may occur among first-degree relatives, 
indicating heterogeneity in the natural course of beta-cell autoimmunity. These results 
were later confirmed in a larger set of individuals, when it was shown that not all first-
degree relatives with multiple autoantibodies and/or signs of impaired beta-cell function 
progressed to type 1 diabetes within a mean follow-up of 2.8 years (254). Results from 
the Childhood Diabetes in Finland (DiMe) Study further supported the heterogeneous 
nature of beta-cell destruction (261). The dual-parameter model was tested 
retrospectively in 13 siblings who progressed to clinical type 1 diabetes, and no 
significant correlations were observed between the duration of the preclinical period, 
first-phase insulin response and the levels of IAA. In addition, there were no specific 
characteristics that could completely discriminate between the progressors and non-28 
progressors. These results were thought to reflect substantial non-predictable individual 
variation in the disease process, so that linearly progressive beta-cell destruction might be 
an exception rather than a common phenomenon in preclinical type 1 diabetes. 
Several studies indicate that autoantibodies may appear at any age, and that they can 
even be detected in infancy (262-265). There is also strong evidence that autoantibodies 
appear sequentially rather than simultaneously, although controversy remains regarding 
their order of appearance. The results of the German BABYDIAB Study (263) and the 
DAISY Study from Denver (265) indicate that autoantibodies are unlikely to appear in 
any common order. In the BABYDIAB Study all of them (ICA, IA-2A, GADA and IAA) 
were seen as the first antibody specificity in some cases when observing the offspring of 
parents with type 1 diabetes from birth. The DAISY Study reported six patterns of 
autoantibody appearance in siblings and offspring of patients with type 1 diabetes. These 
results are partly in contrast with those observed in NOD mice, where autoantibodies and 
T-cell responses to GAD preceded the autoimmune responses to all other antigens (209, 
210). The results indicate that there may not be one primary autoantigen, but that any of 
the known autoantigens could serve as a target for the initial insult of beta-cell 
autoimmunity. Alternatively, the key primary autoantigen may still remain unidentified. 
Only a few studies have been published regarding the temporal pattern of 
autoantibodies during the preclinical phase of type 1 diabetes. It has been thought that 
once autoantibodies emerge their levels remain fairly stable until the onset of overt type 1 
diabetes and decline thereafter, although some fluctuation in antibody status may occur 
(253, 260). In contrast, Bonifacio et al. have recently indicated that humoral beta-cell 
autoimmunity may be a highly dynamic and active process during the early preclinical 
phase of the disease (255). They studied autoantibody titres and subclasses prospectively 
starting from birth in 26 autoantibody-positive offspring of parents with type 1 diabetes. 
They found that the appearance of autoantibodies was characterised by an early IgG1 
subclass peak response to one or more beta-cell antigens. In some subjects this led to 
acute fulminant beta-cell destruction and clinical onset of type 1 diabetes, whereas in 
others the levels of antibodies declined markedly and humoral responses to other antigens 
emerged sequentially over several years. The timing of disease onset in relation to the 
autoantibody responses also varied between individuals, since some subjects presented 
with clinical disease during the peak response whereas others had declining antibody 
levels at the time of the onset of type 1 diabetes. The authors suggested that type 1 
diabetes has an early acute phase of beta-cell autoimmunity which either results in rapid 
progression or proceeds to a chronic autoimmune disease with changing activity. 
2.5. Assessment of the risk of progression to type 1 diabetes 
The long prodromal period before the clinical manifestation of type 1 diabetes offers an 
opportunity to identify those individuals in whom the autoimmune attack on the 
endocrine pancreas has started. It is not known, however, whether the autoimmune 
process, once it has been initiated, inevitably leads to complete destruction of the insulin-
producing cells and clinical manifestation of type 1 diabetes (254, 266). The prediction of 29 
type 1 diabetes, i.e. assessment of the risk of progression to overt disease, has therefore 
been one major goal in diabetes research during the last twenty years. Humoral, genetic 
and metabolic markers have all proved to be useful predictive tools.  
Research into the prediction of type 1 diabetes is indispensable for several reasons. 
Firstly, knowledge of the autoimmune markers of an ongoing disease process can help us 
to resolve and understand the pathomechanism(s) leading to the disease. Secondly, the 
resulting data are used for counselling families having members with type 1 diabetes. 
Thirdly, the identification of risk individuals is a prerequisite for any intervention aimed 
at delaying or preventing manifestation of the clinical disease, and therefore an accurate 
method for risk assessment will be needed as long as there are no intervention method 
that can target the whole population. When the pathomechanism of type 1 diabetes has 
been resolved and a cure for the disease identified, it will be possible to integrate a 
relevant screening strategy into the normal health care system. This will undoubtedly be 
reasonable in countries such as Finland with an extremely high and increasing incidence 
of type 1 diabetes. 
Three variables are often used to express the predictive characteristics of a marker. 
Sensitivity tells us what proportion of the subjects with the disease can be identified by 
means of the marker in question, whereas specificity tells us the proportion of healthy 
individuals correctly identified by a negative test value. The positive predictive value 
(PPV) tells us what proportion of the subjects with the marker in question progress to the 
disease. An optimal predictive test would have a sensitivity, specificity and PPV all of 
100%. In practice, a high specificity will inevitably result in a loss of sensitivity and vice 
versa. A sensitive test is needed when the maximal number of the subjects who progress 
to the disease needs to be identified, whereas a more specific test is needed when those 
who will be the most likely to contract the disease are to be identified, e.g. for 
intervention purposes. Furthermore, the PPV of a test is dependent on the prevalence of 
the disease in the population tested, and therefore needs to be defined in various 
populations. Two major target populations in risk assessment for type 1 diabetes are first-
degree relatives of existing patients and the general population. 
2.5.1. First-degree relatives of patients with type 1 diabetes 
First-degree relatives of patients with type 1 diabetes, i.e. siblings, fathers, mothers and 
offspring, form a special risk population, since they have a substantially higher risk of 
progression to overt type 1 diabetes than those with a negative family history. Most of the 
data regarding measures for predicting type 1 diabetes have therefore accumulated from 
studies on first-degree relatives. The series have mostly been relatively small, however, 
not population-based and comprise both siblings and parents. In addition, the time 
interval between diagnosis of the index case and the obtaining of samples from other 
family members also varies substantially. 30 
2.5.1.1. Humoral risk markers 
Since the original report on the presence of ICA in sera from patients with type 1 diabetes 
(126), the role of autoantibodies as predictive markers has been studied extensively. The 
first evidence that autoantibodies precede the clinical manifestation of type 1 diabetes 
was reported in the early 1980's. Gorsuch et al. analysed ICA prospectively in 582 
unaffected first-degree relatives of patients with type 1 diabetes, and found that ICA was 
detectable in 7% of the parents and 20% of the siblings (267). Furthermore, all four 
siblings and two parents who progressed to clinical type 1 diabetes were persistently 
positive for ICA throughout the observation period. Thereafter, several studies have been 
conducted in order to elucidate the predictive characteristics of ICA and other 
autoantibodies for progression to type 1 diabetes. The four major autoantibody 
specificities currently used to predict the risk of type 1 diabetes are ICA, IAA, GADA 
and IA-2A. 
The reported frequency of ICA among first-degree relatives has varied from 2.6% to 
7.8% (266, 268-272), although methodological differences, i.e. variation in the detection 
thresholds used for antibody positivity and the heterogeneity of the populations, hamper 
direct comparison of the results. Less extensive studies are available concerning the 
prevalence of the other autoantibody specificities. The reported frequency of IAA among 
first-degree relatives is close to 3%, that of GADA close to 5% and that of IA-2A close to 
2.5% (150, 227, 229, 257, 271, 272). Whether the autoantibody frequencies among first-
degree relatives really differ between various countries or simply reflect methodological 
variation is not known.  
The Bart's-Windsor family study represents the first large prospective attempt at 
defining the predictive characteristics of islet autoantibodies. In the two initial reports on 
719 first-degree relatives, the PPV of ICA above the detection threshold was observed to 
be almost 40% (273, 274). In addition, the risk of progression to type 1 diabetes was 
shown to be closely related to the ICA titre, since raising the cut-off limit for ICA 
positivity markedly increased the PPV and specificity (274). This resulted in reduced 
sensitivity, however. The subjects in the Bart's-Oxford family study were later included in 
the same population (275, 276), and the cumulative risk for ICA-positive (≥20 JDF-u) 
subjects of progression to type 1 diabetes within 15 years was recently reported to be 
47% (266). It should be noted, however, that the median follow-up time in these subjects 
is only four years and the age range is wide (2-59 years). Another extensive family study 
is that being carried out in Florida, in which 15224 first-degree relatives of patients with 
type 1 diabetes have so far been screened for ICA (272, 277, 278). Follow-up information 
has been available on 7794 of them, and the ICA-positive subjects were reported to have 
almost 50% cumulative risk of progression to type 1 diabetes (272). In the Seattle Family 
Study, 85 ICA and/or IAA-positive first-degree relatives have been prospectively 
followed up for a mean of 2.8 years (254, 260). Fifty of the 79 ICA-positive subjects had 
progressed to clinical type 1 diabetes, yielding a PPV of 63%. Other family studies have 
reported the PPV of ICA to be 40-60% (269, 279, 280). The reported sensitivity of ICA 
varies from 60% to 80% (269, 272, 280, 281), and the reported specificity is close to 97% 
(269, 272, 274). Interpretation of all the above results is nevertheless hampered by the 31 
fact that the populations are heterogeneous in age distribution, relationship to the diabetic 
proband and length of follow-up.  
Ziegler and colleagues studied the risk of progression to type 1 diabetes in relation to 
IAA in 1712 first-degree relatives, including 689 siblings, 353 parents and 628 offspring 
(257). Life-table analysis revealed that the relatives with IAA had a 53% risk of 
progression within 5 years of follow-up, compared with 65% for the ICA-positive 
relatives. The PPV was further increased to 77% by combining the two markers, and 
reached 100% for the ICA-positive subjects with high levels of IAA (>150 nU/ml). 
Others have subsequently confirmed the utility of IAA as a predictive marker for 
progression to type 1 diabetes, especially when combined with ICA (270, 272, 276, 279). 
The reported sensitivity of IAA has varied from 24% to 76% (254, 257, 270, 272, 279, 
280). 
Since the identification of the 64kD beta-cell protein as an autoantigen in type 1 
diabetes (127) and its further characterization as glutamic acid decarboxylase (183), the 
usefulness of GADA as predictive markers has been studied extensively. In 1987, 
autoantibodies to the 64kD protein were reported to precede the clinical onset of type 1 
diabetes in five individuals (282). Several later studies reported these antibodies to be 
present in the sera of first-degree relatives, and to be highly predictive for progression to 
the disease. Most of the data have been obtained from studies on highly selected 
individuals initially screened for ICA and/or IAA, however (276, 283-288), and therefore 
the exact predictive characteristics of GADA have remained poorly defined. The reported 
PPV of GADA has varied from 30% to 50% (272, 279, 280), and the sensitivity from 
60% to 90% (272, 279, 280, 289). Some authors have indicated that GADA, especially 
when present in high titres, may be related to a slower or reduced risk of progression to 
type 1 diabetes (266, 290). 
More recently, IA-2A have been added to the panel of major humoral risk markers of 
type 1 diabetes (228, 276, 291). These antibodies seem to be highly predictive of type 1 
diabetes and more specific for it than the others. There is also evidence that IA-2A may 
be related to a rapid progression to type 1 diabetes, although this has not been definitely 
confirmed (266, 292). Verge et al. studied nearly 800 first-degree relatives, and reported 
the 5-year cumulative risk of type 1 diabetes to be 81% in those with IA-2A and the 
sensitivity of these antibodies to be 64% (279). Elsewhere, seven siblings out of 481 were 
found to have IA-2A and four (57%) of these progressed to type 1 diabetes. Since only 
one other subject had progressed to type 1 diabetes, this yielded a sensitivity of 80% for 
IA-2A (227). In a recent German study, 33 out of more than 1600 first-degree relatives 
tested positive for IA-2A, and 16 of these progressed to type 1 diabetes. The PPV of IA-
2A was therefore 48%, and the reported sensitivity was 67% (280). A large U.S. family 
study failed to reliably specify the predictive characteristics of IA-2A, however, since 
only 5% of the initial population was tested for these autoantibodies, and the population 
tested was skewed towards ICA positivity (272). Therefore, no definitive results have 
been available to determine the exact predictive characteristics of IA-2A in first-degree 
relatives. 
Combinations of autoantibody markers have proved to be of great value for the 
prediction of type 1 diabetes. The presence of multiple antibodies indicates a high risk of 
future disease, and each of the autoantibodies had a low prognostic significance when 
detected in the absence of the others. Bingley et al. reported that first-degree relatives 32 
who tested positive for ICA had a 43% risk of developing type 1 diabetes over 10 years, 
and the risk was further increased to 84% when this marker was combined with IAA, 
61% when it was combined with GADA, and 76% when it was combined with 37-kD 
antibodies (IA-2A) (276). In addition, the risk increased with the number of 
autoantibodies detected, from 8% for ICA alone to 88% for three or more autoantibodies. 
Another study showed that the presence of two or more out of IAA, GADA and IA-2A is 
highly predictive of the development of type 1 diabetes, and that the estimated 5-year risk 
was indeed 100% for those having all three antibody specificities (279). Similar results 
regarding the relation between the number of autoantibodies and the risk of progression 
to type 1 diabetes have been reported elsewhere (254, 266, 272, 276, 280, 293, 294). 
None of the antibody combinations has consistently been shown to be superior to any 
other, although it has been suggested that ICA screening could be replaced with 
combined detection of GADA and IA-2A (276, 279, 281).  
2.5.1.2. Genetic risk markers 
As genes are stable inherited characteristics of an individual, genetic screening offers 
fascinating possibilities for the identification of subjects who are susceptible to a disease 
before the disease process has even started. The major genetic determinants of 
susceptibility to type 1 diabetes resides in the HLA region, and almost 90% of patients 
with type 1 diabetes carry susceptible HLA-DR and HLA-DQB1 alleles. These alleles are 
also frequent in healthy individuals, however, resulting in a conspicuously low specificity 
for them as markers. Therefore genetic markers seem to have a limited value for 
predicting type 1 diabetes when used alone. On the other hand, most of the recent data 
have accumulated from series of patients with diabetes, and very few prospective studies 
are available. The predictive characteristics of genetic markers have therefore not been 
well established. In particular, there has been shortage of data on the relationships 
between autoantibodies and genetic markers and on the utility of combinations of these 
markers for predicting type 1 diabetes.  
The degree of HLA identity with the diabetic proband in the family has been shown to 
be associated with disease risk. Siblings sharing two haplotypes, i.e. HLA-identical 
siblings, have a 10-30% risk of developing type 1 diabetes before the age of 30 years, 
whereas HLA-haploidentical and HLA-non-identical siblings have a substantially lower 
risk (269, 273, 295, 296). The predictive value of the HLA-DR3/4 phenotype was 
reported to be 12% in 536 siblings (269) and 19% in another of 234 siblings (297). The 
HLA-DQB1*02 and DQB1*0302 alleles and the genotypes including these have also 
been shown to be related to an increased risk of progression to type 1 diabetes (279, 298-
300). In contrast, the HLA-DQB1*0602 allele was reported to predominantly protect 
carriers from type 1 diabetes (272, 279, 299, 301), or to be extremely rare in siblings who 
progress to the disease (298).  
It has been suggested that combining genetic markers and autoantibodies may enhance 
the prediction of type 1 diabetes. Deschamps and colleagues observed that HLA markers 
contributed significantly to the risk when combined with ICA, since ICA-positive 33 
siblings carrying the HLA-DR3/4 phenotype had a 58% cumulative risk of progression to 
type 1 diabetes within 8 years (269). In a recent series of 234 French siblings, a 
combination of the DR3/4 phenotype with the presence of more than one autoantibody 
yielded a PPV of 67% (297). The HLA-identical siblings in the Finnish DiMe study with 
high levels of ICA had a PPV of 77% over 4.7 years of follow-up (270). 
2.5.1.3. Metabolic risk markers 
Since type 1 diabetes results from insulin deficiency, it is logical to regard beta-cell 
function, i.e. insulin secretory capacity, as a marker of the disease process. Several 
attempts have therefore been made to ascertain the utility of beta-cell function tests for 
predicting progression to type 1 diabetes. The first-phase insulin response (FPIR) to 
intravenous glucose has proved to be the most sensitive measure of beta-cell function, 
whereas the oral glucose tolerance test (OGTT), for example, is of no significant value in 
this respect. The FPIR is an indirect measure of beta-cell mass, however, and thus 
impairment of this response does not necessarily reflect simply the degree of beta-cell 
destruction. Even so, a low FPIR has been shown to be related to a markedly increased 
risk of progression to type 1 diabetes. In addition, autoantibodies are usually detected 
simultaneously with deteriorating FPIR, indicating that the decrease in beta-cell function 
is due to an immune-mediated destructive process in the endocrine pancreas. 
It was shown in a prospective study of monozygotic triplets and twins who were 
initially discordant for type 1 diabetes that the presence of ICA was temporally associated 
with a progressive decline in beta-cell function in the preclinical period (302). The same 
group also screened 1723 first-degree relatives, and reported an abnormally low FPIR in 
50% (6/12) of the ICA-positive non-diabetic relatives, emphasizing the value of FPIR to 
intravenous glucose for the detection and monitoring of early preclinical beta-cell 
dysfunction (303). They also performed sequential intravenous glucose tolerance tests 
(IVGTT) on nine ICA-positive subjects before the clinical manifestation of type 1 
diabetes, and showed a markedly linear progressive loss of beta-cell function during the 
preclinical period (252). In another study it was suggested that the combination of ICA 
screening and IVGTT identifies relatives with a very high risk of progressing to overt 
diabetes, since 15 (88%) out of a series of 17 ICA-positive first-degree relatives with a 
low FPIR progressed to overt type 1 diabetes (304). A French study aimed at assessing 
the adequacy of FPIR for predicting type 1 diabetes in 220 unaffected first-degree 
relatives (194 siblings and 26 offspring) of patients with type 1 diabetes (305) pointed to 
a wide variation in FPIRs between the individuals. The sensitivity, specificity and PPV of 
at least two low FPIRs during the prospective follow-up were reported to be 60%, 69% 
and 43%, respectively, and the highest PPV (75%) was achieved by a combination of 
consistent ICA-positivity, consistently low FPIR and the HLA-DR3/4 phenotype. The 
authors could not predict the time to the onset of type 1 diabetes from the decline in 
FPIR, however, and they concluded that IVGTTs can be used to predict the disease but 
not its clinical onset. In another family study, all subjects (<18 years of age) with 
detectable ICA on two occasions and a FPIR <67 µU/ml progressed to type 1 diabetes, 34 
although the total number of progressors was low (306, 307). In the DiMe Study, 
sequential IVGTTs were performed on 13 initially ICA and/or IAA positive siblings who 
progressed to type 1 diabetes and on 30 ICA and/or IAA positive siblings who did not 
present with the clinical disease within 3.8 years of follow-up (261). The FPIRs in the 
initial and subsequent IVGTTs were significantly lower in the progressors than in the 
non-progressors, and the PPV of a FPIR <35 mU/l was 100%. The FPIR was not related 
to the period of time elapsing before diagnosis, however, and therefore could not be used 
to predict the duration of the preclinical period. Later, a low FPIR in the first IVGTT was 
shown to be closely associated with the development of type 1 diabetes in these siblings 
irrespective of the genetic markers carried by the individual, although an abnormally low 
FPIR was also seen in five siblings who did not progress to overt type 1 diabetes (308). 
Subclinical, non-progressive beta-cell dysfunction has also been reported in the Seattle 
Family Study (254, 260).  
In order to elucidate problems related to the interpretation of the results obtained in 
different laboratories, a consensus protocol for the performance of IVGTT was published 
in 1992 (309). Furthermore, a large international collaborative study, ICARUS (the Islet 
Cell Antibody Register Users Study), attempted to maximize the currently available data 
regarding assessment of the risk of developing type 1 diabetes in ICA-positive first-
degree relatives at more than 20 research centres. The interactions of age, ICA, IAA and 
FPIR in predicting the risk of progression were studied in 456 subjects, of whom 108 had 
progressed to type 1 diabetes (310). All of these variables were reported to enhance the 
risk of the disease, and the predictive value of each of them was modified by the presence 
or absence of the others. The risk of type 1 diabetes was observed to be highest (85%) in 
family members with a markedly low FPIR (<50 mU/l), and Cox regression analysis 
revealed that a low FPIR made the strongest contribution to the calculated risk, followed 
by IAA and ICA, and then age. Due to reports of controversies, the exact roles of IVGTT 
and FPIR in the assessment of the risk of progression to type 1 diabetes in first-degree 
relatives remains partly open. 
2.5.2. General population 
Studies of first-degree relatives of patients with type 1 diabetes are important in order to 
elucidate the pathogenesis and preclinical course of type 1 diabetes and to conduct 
intervention trials. More than 90% of new patients diagnosed are sporadic, however, and 
do not have affected first-degree relatives. Therefore the current focus of research on the 
prediction of type 1 diabetes is moving towards the general population. Strategies for 
identifying risk individuals at the population level are urgently needed, and it remains 
unclear whether the same risk markers that are used for predicting familial type 1 
diabetes are directly applicable at the population level (311-313). Only a few prospective 
studies are available on the prediction of type 1 diabetes in the general population. 35 
2.5.2.1. Predictive markers 
Several studies have aimed at determining the prevalence of ICA in the general 
population, whereas substantially less is known about the prevalence of other diabetes-
associated autoantibodies. The frequency of ICA in healthy schoolchildren has been 
reported to be around 0.5% in Japan, Netherlands, Spain and the United States (146, 311, 
314, 315). Two German studies placed their prevalence at close to 1% (316, 317), while a 
large French study of more than 13000 schoolchildren arrived at a frequency of 1.5% 
(312). Higher prevalences have also been reported, almost 2.5% in England (318, 319) 
and almost  4% in Sweden and Finland (167, 320, 321). Direct comparison of the 
reported frequencies of ICA is difficult, e.g. due to the different thresholds for antibody-
positivity used. It is therefore not known whether the observed differences in the 
prevalence are due to methodological factors or really reflect true variation between 
countries.  
The reported prevalence of IAA in the general population has ranged from 0.35% to 
3% (167, 311, 315, 317, 319), while only three reports are available on the prevalence of 
GADA and two on that of IA-2A. The frequency of GADA was observed to be 4.1% in 
412 healthy Swedish children (167). When more than 2500 healthy schoolchildren were 
screened for autoantibodies in the Oxford region of England, the frequencies of GADA 
and IA-2A were reported to be 2.2% and 2.1%, respectively (319). More recently, the 
large prospective Karlsburg Type I Diabetes Risk Study in Germany recruited nearly 
9500 schoolchildren for antibody analyses and detected GADA and IA-2A in 3.0% and 
2.4% of them, respectively (317). Interpretation of the results concerning the prevalence 
of IAA, IA-2A and GADA is hampered by the fact that the definition of antibody 
positivity varies widely. In the two latter studies, for example, the 97.5
th and the 98
th 
percentiles of the antibody levels in the population were used as cut-off levels for 
antibody positivity. These results emphasize the urgent need for international 
standardisation of the assays for GADA and IA-2A, as has been attempted for the ICA 
and IAA assays. The observed frequencies of various autoantibodies indicate, however, 
that their prevalence in general population is considerable higher than that of type 1 
diabetes. 
The predictive characteristics of autoantibodies in the general population have been 
determined in only very few cases. In a prospective Dutch study of 4806 schoolchildren, 
ICA were present in eight subjects and four of them progressed to clinical type 1 diabetes 
within 10 years of follow-up (314). These eight ICA-positive subjects and three initially 
ICA-negative ones who progressed to type 1 diabetes were later tested for GADA, which 
were detected in six of the former and one of the latter (322). The authors suggested that 
while GADA may have a higher sensitivity than ICA for type 1 diabetes, the combination 
of the two increases the specificity of the prediction. The estimated risk of type 1 diabetes 
was reported to be 28% over 5 years and 48% over 7 years in ICA-positive 
schoolchildren in Florida, indicating that ICA predicts type 1 diabetes as efficiently in the 
general population as in first-degree relatives (311). Other studies have not supported this 
finding, and a marked difference was reported recently in the PPV of ICA in siblings 
(40%) as compared with subjects from the general population (6%) (313). Two cross-
sectional studies have tried to estimate the predictive characteristics of autoantibodies in 36 
the general population. In Sweden, the PPVs of ICA, GADA and IAA were estimated to 
be 4.1%, 3.4% and 4.0%, respectively, in a series of nearly 400 healthy children (167). 
Bingley et al. reported the estimated risks of progression to type 1 diabetes between the 
ages of 10 and 20 years to be 6.7% for ICA, 6.6% for GADA, 5.6% for IA-2A and 4.8% 
for IAA when the 97.5th percentile was used as the cut-off level for antibody positivity 
(319). The estimated risk was markedly increased with higher cut-off levels, but this 
resulted in a substantial loss in sensitivity. They also demonstrated that the estimated risk 
was related to the number of autoantibodies, being 0.2% for those with one antibody 
specificity, 9% for those with two, 59% for those with three and 61% for those with four. 
In the prospective Karlsburg Type I Diabetes Risk Study, six schoolchildren had 
progressed to type 1 diabetes within a mean of 1.5 years of follow-up, all of them being 
positive for multiple autoantibodies (317). In the same study, an IVGTT was performed 
on 17 of the 22 subjects who were positive for two or more autoantibodies and FPIR was 
markedly decreased in 10 (60%) of them. The predictive values of the individual 
antibodies were not estimated, however, probably due to the low number of progressors 
and/or because not all the children were observed for progression to type 1 diabetes. 
Taken together, the predictive characteristics of humoral, genetic and metabolic markers 
are poorly defined in the general population, and extensive prospective studies are needed 
before predictive and preventive strategies can reliably be applied at the population level. 
2.5.3. Predictive strategies 
A number of researchers have introduced strategies for assessing the risk of progression 
to type 1 diabetes (e.g. 323, 324). One major observation is that a combination of 
autoantibodies offers better predictive power than testing for any single marker, both in 
first-degree relatives and in the general population. Despite several proposed models and 
the reasonable predictive estimates obtained using them, it remains unresolved who, 
when and how frequently we should screen in order to achieve optimal prediction. 
Extensive follow-up studies dissecting the natural history of type 1 diabetes both in first-
degree relatives and in the general population are therefore urgently needed. 
Bingley et al. present a decision tree model (Fig. 2) (276, 325), which considers the 
baseline risk based on a positive or negative family history of type 1 diabetes. The 
selection of individuals for further testing then continues stepwise in both groups by 
testing for humoral, genetic and metabolic markers with certain empirically defined 
selection criteria. The advantage of this model is that the test variables and the selection 
criteria for the next steps can be modified according to recent research data. The purpose 
of the prediction defines the variables that are included in the decision tree and the 
predictive strategy used, i.e. whether the individuals at highest risk or all those with any 
degree of risk are to be identified. More recently, the same authors have also proposed 
specific alternative strategies for autoantibody-based risk assessment in first-degree 
relatives of patients (281). All the alternatives include two-step screening for 
autoantibodies. They propose that both the primary and secondary testing should be as 
sensitive as possible. The suggested primary screening is testing either for low titre ICA, 37 
for the combination of IA-2A and GADA, or for the combination of IAA and GADA. 
These identify 61%, 83% and 87% of the future cases, respectively. Several different 
antibody combinations are presented as a second line of testing, all of them identifying 
subgroups with higher risk but not differing with regard to the risk estimates. They also 
observe that the sensitivity of individual markers is affected by age, so that different 
strategies should probably be used to identify risk individuals in younger and older 
populations. They conclude that it is not necessary to measure all four antibody 
specificities, since equivalent performance can be achieved using several strategies that 
involve two or more steps. ICA could therefore be replaced with primary screening for 
either GADA and IA-2A or GADA and IAA, but ICA remain useful as a second-line 
screening tool. These strategies would efficiently reduce the costs of risk assessment. 
Several other groups have also proposed similar two-step models recently (271, 280, 
294). 
 
 
 
 
 
Fig. 2. The decision tree for estimation of the risk of progression to type 1 diabetes. 
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Bingley et al. have also proposed a strategy of predictive screening for type 1 diabetes 
in the general population (319). In their cross-sectional study of 2855 schoolchildren and 
133 children with type 1 diabetes, they evaluated strategies based on initial testing for 
GADA and IA-2A followed by testing for ICA and/or IAA. In their first-line screening 
for GADA and IA-2A, 3% of the schoolchildren and 89% of the patients were identified 
yielding an estimated risk of 6% for progression to type 1 diabetes. Upon second-line 
testing for ICA and/or IAA with different positivity thresholds, subgroups were identified 
with a risk varying from 36% to 78%. Batstra et al. have presented another proposal for 
antibody-based risk assessment in the general population (326). Their proposal includes 
three steps of screening for multiple beta-cell autoantibodies. Firstly, infants from the 
general population would be recruited for screening. This could be preceded by 
preselection based on genetic susceptibility markers. Thereafter these infants would be 
screened for multiple beta-cell autoantibodies at an age between one and two years, and 
those testing positive for multiple autoantibodies, and possibly also those having high 
titres of a single autoantibody specificity, would be recruited for intervention. Subjects 
positive for a single antibody specificity with low titres and those who are negative for all 
autoantibodies would be screened again for multiple autoantibodies 1-4 years later. 
Further selection of individuals for intervention or repeated testing would take place in a 
similar manner to the first step. The third test for multiple autoantibodies would be 
performed shortly before puberty. At this time intervention could be offered to 
individuals testing positive for one or more autoantibodies regardless of the titre, and 
only autoantibody-negative subjects would be excluded. The definitions of the thresholds 
for positivity and low and high antibody levels are the major determinants of the 
predictive value achieved by this model, and the number of autoantibodies present rather 
than any specific autoantibody would determine the risk of type 1 diabetes. 
2.6. Preventive strategies 
The major goal of diabetes research is prevention of the disease. Data on animal models 
have suggested that several strategies can be used to prevent the disease (e.g. 327). Along 
with increasing knowledge of its pathogenesis and improved predictive strategies for 
identifying high-risk individuals, the era of clinical intervention trials has started. 
Prevention can be classified into various categories. Primary prevention is implemented 
before the disease process has started and the objective is to avoid initiation of that 
process. Secondary prevention aims at arresting or delaying ongoing progression of beta-
cell autoimmunity and clinical manifestation of the disease. Tertiary prevention can be 
seen either as restoration of endogenous insulin secretion after clinical diagnosis or 
prevention of the consequences of the disease, e.g. long-term complications, in subjects 
with overt type 1 diabetes and end-stage insulitis.  
Both experimental and epidemiological studies have indicated that cow's milk proteins 
may be involved in the pathogenesis of type 1 diabetes. A pilot study testing the 
hypothesis that avoidance of cow's milk proteins in early infancy reduces the cumulative 
incidence of diabetes-associated autoantibodies over the first two years of life in high-risk 39 
individuals in Finland has recently been successfully completed (328, 329). A definite 
international multicentre study "Trial to Reduce IDDM in the Genetically at Risk", 
TRIGR, is planned to start shortly (329, 330). This will recruit newborn infants who have 
a first-degree relative with type 1 diabetes and who carry one or both HLA-DQB1 risk 
alleles. After breast-feeding, these high-risk infants will receive either a protein 
hydrolysate or conventional cow's milk-based infant formula, and serological markers 
and progression to type 1 diabetes will be monitored up to 10 years of age.  
Several trials have been initiated in terms of secondary prevention of type 1 diabetes 
in high-risk individuals with signs of ongoing beta-cell autoimmunity (see 331 and 332). 
Two large multicentre trials have been organized to define the value of nicotinamide for 
this purpose (333-335). The German Nicotinamide Intervention Trial (DENIS) was 
focused on children below 12 years of age, but it was was discontinued in 1997 after it 
was observed that nicotinamide was not capable of reducing the incidence of type 1 
diabetes by 80% in the population concerned. The European Nicotinamide Diabetes 
Intervention Trial (ENDIT) includes autoantibody-positive first-degree relatives up to the 
age of 40 years, who receive either a high dose of oral nicotinamide or a placebo daily, to 
test whether the agent is able to reduce the incidence of type 1 diabetes. The ENDIT will 
be completed in year 2003. The DPT-1 intervention trial evaluates whether oral or 
subcutaneous insulin can delay the presentation of type 1 diabetes (336). This approach is 
based on the hypothesis that insulin, as an antigen-specific therapy, may modulate the 
immune response and induce tolerance. Recombinant human insulin is given parenterally 
or orally to high-risk first-degree relatives of patients with type 1 diabetes. Similar 
approaches have also been started in other centres in U.S. and Europe (see 331). 
Intranasal administration of insulin is another approach to the antigen-specific prevention 
of type 1 diabetes. In the Finnish "Type 1 Diabetes Prediction and Prevention Study" 
(DIPP) (329, 337) all newborn infants in three university hospitals are offered genetic 
screening for HLA-DQB1 risk alleles. Those who have an increased genetic risk are 
monitored for disease-associated autoantibodies and progression to type 1 diabetes up to 
15 years of age. Intranasal insulin is started in those identified as being at the highest risk, 
defined by persistent presence of multiple autoantibodies. Conclusive results from all of 
the above-mentioned intervention trials concerning the effectiveness of insulin in 
preventing and/or delaying the disease process will be available within the next 5-10 
years. 3.  Purpose of the study 
The objectives of the present work were: 
 
1.  to assess the value of disease-associated autoantibodies for estimating the risk of 
progression to type 1 diabetes in siblings of children with type 1 diabetes. 
 
2.  to investigate the relationships between genetic risk markers and autoantibodies, 
and to define the value of combined use of these markers for estimating the risk 
of progression to type 1 diabetes in siblings of affected children. 
 
3.  to characterise the preclinical course of type 1 diabetes in siblings of children 
with type 1 diabetes. 
 
4.  to assess the prevalence of disease-associated autoantibodies and their 
relationships to genetic markers and progression to type 1 diabetes in healthy 
schoolchildren. 
 
5.  to investigate temporal changes in autoantibody positivity and the relationships 
between autoantibodies, genetic risk markers and beta-cell function in healthy 
schoolchildren. 4.  Subjects and methods 
4.1. Subjects 
The study populations included in this work are presented in Table 2. The subjects in 
papers I-III comprised siblings from the Childhood Diabetes in Finland (DiMe) study 
(338), a population-based, nationwide survey initiated at the beginning of September 
1986, to investigate the role of genetic, immunological and environmental factors in the 
development of type 1 diabetes. All newly diagnosed children with diabetes less than 15 
years of age, their siblings under 20 years of age and their parents were invited to the 
study. Informed consent was obtained from the subjects and/or their parents. The ethical 
committees of all 31 participating hospitals approved the study design. The recruitment 
of new cases terminated at the end of April 1989, by which time 801 eligible index cases 
had been diagnosed, with a total of 977 unaffected siblings younger than 20 years of age. 
The initial blood sample from each sibling was obtained at or close to the diagnosis of the 
index case. Subsequent blood samples were taken at intervals of three to six months over 
the first two years and at intervals of six to 12 months thereafter up to four years. Serial 
samples were continued to be taken from the siblings testing positive for ICA on at least 
one occasion at intervals of 12 months or less. All the siblings were observed for 
progression to type 1 diabetes. Observation of the siblings progressing to type 1 diabetes 
ended at diagnosis. The diagnosis was based on clinical symptoms and an increased 
random blood glucose concentration (>10 mmol/l) or elevated fasting (>6.7 mmol/l) or 
random blood glucose (>10 mmol/l) on two occasions in the absence of symptoms (339). 
There were 755 siblings (77.3%) from whom at least one blood sample was available, 
and these were taken to comprise the study population in paper I. The series included 349 
boys (46%) and had a mean age 9.9 years (range 0.8-19.7 years) at the time of the first 
sample. The median duration of follow-up for those who remained unaffected was 9.1 
years (end of May 1997) (range 7.7-10.7 years). ICA, IA-2A, GADA and IAA were 
determined in the initial samples from all subjects. 
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Table 2. Summary of the study populations included in this work. 
_______________________________________________________________________ 
 
P a p e r   S u b j e c t s          N u m b e r  
________________________________________________________________________ 
I Initially unaffected siblings of children with type 1 diabetes (DiMe) 755 
II  Initially unaffected siblings of children with type 1 diabetes (DiMe)  701 
III  All the initially unaffected siblings who have progressed to  
  type 1 diabetes during the follow-up (DiMe)       39 
  Matched control siblings who have not progressed to type 1 diabetes  39 
IV  Initially unaffected Finnish schoolchildren        3652 
V  ICA and/or GADA-positive initially unaffected Finnish schoolchildren  104 
  Autoantibody-negative matched control children      104 
_______________________________________________________________________ 
 
 
In paper II, the study population comprised 701 of the 755 above-mentioned siblings 
(paper I) in whom HLA A, B, C and DR typing was available. HLA-DQB1 genotyping 
was performed on 565 (80.6%) of these. Half-siblings were not included in the study 
population. The series included 324 boys (46%) and had a mean age of 9.9 years (range 
0.8-19.7 years) at the time of the first sample. All of these siblings were observed up to 
the end of August 1998, unless type 1 diabetes was diagnosed before that date. The 
median follow-up time for those who had not progressed to type 1 diabetes was 10.3 
years (range 8.9-12.0 years). 
The subjects in paper III included all 39 siblings from the DiMe-study who have 
progressed to clinical type 1 diabetes during prospective observation for a median of 10.7 
years (range 9.7-12.3 years) up to the end of year 1998. In addition, 39 siblings who have 
not presented with the disease, were matched as close as possible for sex, age (± two 
years in 90% of the subjects) and the initial number of autoantibodies (same number in 
nine subjects, ± one antibody in 14 subjects, ± two antibodies in 11 subjects and ± three 
antibodies in five subjects). Autoantibodies were measured in sequential follow-up 
samples of these subjects. In addition, sequential IVGTTs were performed at intervals of 
six months over the initial two years and at 12 months intervals thereafter, and most of 
these subjects participated in at least one IVGTT.  
The subjects in paper IV comprised 3652 healthy Finnish schoolchildren. The study on 
beta-cell autoimmunity in schoolchildren was initiated at the beginning of 1994, and all 7 
to 16-year-old schoolchildren (n=4280) living in five municipalities in northern Finland 
(Haapajärvi, Ii, Oulainen, Yli-Ii and Ylikiiminki) were invited to take part in the study. 
Informed consent was obtained from the subjects and/or their parents. The Ethics 
Committee of the Faculty of Medicine, University of Oulu, approved the study design. 
The children and/or their parents were asked to complete a questionnaire concerning 
various diseases and family history of diabetes. In the questionnaire the subjects were 
asked about their history of allergy, inflammatory bowel diseases, coeliac disease, 
diabetes, other endocrine diseases, rheumatoid diseases or thyroid diseases, and when the 
disease was diagnosed and in which hospital the patient had been treated. They were 
asked whether and when they have had pertussis, scarlet fever or roseola infantum 45 
(exanthem subitum). They were also asked whether and when they have had any of the 
following infections over the preceding 12 months: common flu (cough and rhinitis), 
bronchitis, pneumonia, tonsillitis, otitis media, gastroenteritis (vomiting and/or diarrhea), 
stomatitis, urinary tract infection or any other specific infection. In addition, the family 
history of diabetes was elicited specifically, i.e. whether siblings, father, mother or 
grandparents have/had diabetes and which type of diabetes. Seventeen subjects (0.4%) 
had clinical type 1 diabetes at the time of recruitment for the study. Information on the 
HLA genotype was available in 15 of these children, out of whom six (40%) were 
DQB1*02/0302 heterozygous, four (27%) carried the DQB1*0302/x genotype (x other 
than *02, *0301 or *0602-3) and three (20%) the DQB1*02/y genotype (y other than 
*0302, *0301 or *0602-3). One had the DQB1*0302/*0602 genotype and one the 
DQB1*02/0301 genotype. Serum samples were collected from 3662 subjects (85.6%) 
who gave their consent. Ten of these were later excluded, as they already had previously 
diagnosed clinical diabetes. Altogether, 3652 schoolchildren (85.3%) were included, and 
all of them were initially analysed for ICA and for GADA. More recently all subjects 
were in addition tested for IAA and IA-2A. Out of these subjects 3625 (99.3%; 84.7% of 
all the schoolchildren) returned a completed questionnaire. The mean age of the subjects 
was 11.7 years (range 6.9-17.6 years) and 48.9% (n=1785) were boys. All 3652 children 
were observed for progression to type 1 diabetes from 1994 to the end of May 1999 for a 
mean period of 5.3 years (range 5.2-5.5 years) using as a source the Central Drug 
Registry of the Social Insurance Institute, which has an ascertainment rate of more than 
99% for new cases of type 1 diabetes. 
In paper V, 106 subjects (2.9%) of the above-mentioned population of schoolchildren 
tested initially positive for ICA and/or GADA. One hundred and four of them and 104 
control children negative for all four antibody specificities and matched for age, sex and 
place of residence, were invited to take part in the second part of the study approximately 
two years after initial screening. Two initially ICA and/or GADA positive subjects were 
excluded, as they progressed to type 1 diabetes before the second part of the study. The 
second part of the study included blood sampling for autoantibody determinations (ICA, 
IA-2A, GADA and IAA), interview/questionnaire, physical examination and an 
intravenous glucose tolerance test (IVGTT). The group of autoantibody-positive children 
comprised 51 boys and 53 girls and their mean age at the time of the IVGTT was 13.7 
years (range 9.4-18.8 years). Two of the antibody positive subjects had a first-degree 
relative with type 1 diabetes (the father of one subject and the mother of the other 
subject) The subjects were asked whether and when they had had upper respiratory tract 
infections, gastroenteritis or other specific infections since the initial blood sampling, and 
whether they had had symptoms associated with diabetes (thirst, excessive drinking, 
weight loss, tiredness). Physical examination included measurement of weight, height 
and waist/hip ratio. Relative weight (actual weight in relation to mean weight for height) 
was assessed based on Finnish growth charts (340). The children were observed for 
progression to type 1 diabetes from the time of the second sampling to the end of May 
1999 for a mean period of 3.4 years (range 3.2-3.6 years). 46 
4.2. Methods 
4.2.1. Islet cell antibodies 
ICA were determined by a standard immunofluorescence method using sections of frozen 
human group O pancreas (126). All sera with detectable ICA were titrated to end-point 
dilution, and the results were expressed in Juvenile Diabetes Foundation (JDF) units by 
comparison with an international standard reference serum (341). The detection limit for 
ICA was 2.5 JDF units. Our laboratory had a sensitivity of 100%, a specificity of 98%, a 
validity of 98% and a consistency of 98% in the fourth round of the international 
workshops on the standardisation of  the ICA assay (341).  
4.2.2. Insulin autoantibodies 
Conventional competitive radiobinding assay was used for detection of IAA in papers I-
III (159). Endogenous insulin was removed with acid charcoal prior to the assay, and free 
and bound insulin were separated after incubation with mono-
125I(Tyr A 14)-labelled 
human insulin (Novo Research Institute, Bagsvaerd, Denmark) in the absence or presence 
of an excess of unlabelled insulin. IAA levels were expressed in nU/ml, where 1 nU/ml 
corresponds to a specific binding of 0.01% of the total counts. The cut-off limit for IAA 
positivity was defined as 54 nU/ml, representing the 99th percentile in a series of 105 
non-diabetic children. The disease sensitivity of the IAA assay was 26% and the disease 
specificity 97% based on 140 samples included in the Multiple Autoantibody Workshop 
(342). 
In papers IV and V, IAA were analysed with a radiobinding micro-assay, modified 
from that described by Williams et al. (168). The serum samples (5 µl) were incubated on 
96-deep-well plates with mono 
125I-(Tyr
A14) -labelled human insulin (Amersham, Little 
Chalfont, Bucks, UK) in the presence or absence of an excess of unlabelled insulin. After 
incubation for 72 hours, the immunocomplexes were precipitated using Protein-A-
Sepharose (Pharmacia Biotech, Uppsala, Sweden). The volume of the incubation reaction 
was doubled by adding the reaction buffer [TBT; 50 mM Tris, pH 8.0, 1 % (v/v) Tween 
20]. After washings with reaction buffer, the samples were transferred to microtitration 
plates, scintillation liquid was added and the bound activity was measured with a liquid 
scintillation counter (1450 MicroBeta Trilux; PerkinElmer Wallac, Turku, Finland). 
Specific binding was expressed in relative units (RU) based on a standard curve run on 
each plate using the MultiCalc
TM software program (PerkinElmer Wallac). The standard 
curve was constructed from nine serial dilutions of a serum from a patient with a high 
IAA titre and a serum from an IAA-negative subject. The cut-off limit for IAA positivity 
was set at the 99th percentile in 371 non-diabetic Finnish subjects (1.56 RU). The 
performance characteristics of this assay was compared to that run in Bristol (168) based 
on a sample exchange comprising 100 samples. There was a strong correlation between 
the two assays (r=0.96; p<0.001), and the concordance rate was 94%. The disease 47 
sensitivity of this microassay was 35% and the specificity 100% based on 140 samples 
derived from the 1995 Multiple Autoantibody Workshop (342).  
4.2.3. Antibodies to glutamic acid decarboxylase 
Antibodies to 65 kD isoform of glutamic acid decarboxylase (GADA) were quantified 
with a radiobinding assay described by Petersen et al. (343). Serum samples (2 µl) were 
incubated overnight in 96-well microtitre plates at 4°C with a total of 30,000 cpm of 
35S-
methionine-labelled  in vitro transcribed and translated human recombinant GAD65 
protein in a total volume of 50 µl TBST (50 mmol/l Tris, 150 mmol/l NaCl, 0.1 vol/vol 
Tween-20, pH 7.4). All the samples were analysed in quadruplicate with and without an 
excess of unlabelled GAD65. Competition analysis was carried out by adding 1 µg 
purified unlabelled GAD65 to the incubation mixture. Immunocomplexes were isolated by 
adding 7.5 mg Protein-A-Sepharose (Pharmacia Biotech) diluted in a total volume of 100 
µl TBST to each well. After incubation for 2 hours at 4°C with shaking, the reaction 
volume was transferred to a 96-well filtration plate (Multiscreen; Millipore, Bedford, 
MA, USA). The filtration plates were placed on a vacuum device (Millipore) and the 
immunocomplexes washed 10 times with 150 µl of cold (+4°C) TBST. After drying for 2 
hours on a tissue paper, each filter containing the immunocomplexes was punched into a 
vial, 2.5 ml scintillation fluid was added (Ultimagold; Packard, Groningen, Netherlands) 
and the radioactivity was measured in a scintillation counter.  
The results are expressed in relative units (RU) representing the specific binding as a 
percentage of that obtained with a positive standard serum; relative GAD unit = 100 x 
[cpm (unknown sample) - cpm (unknown sample incubated with an excess of unlabelled 
GAD) / cpm (positive standard serum) - cpm (positive standard serum incubated with an 
excess of unlabelled GAD)]. The cut-off limit for GADA positivity was defined as 6.5 
relative units (RU), representing the 99th percentile in a series of 372 healthy control 
children. All samples exceeding 2.9 RU (mean + 1 SD in 372 control children) were 
retested in order to confirm GADA positivity or negativity. The disease sensitivity of the 
present assay was 76% and the disease specificity 97%, based on the Multiple Antibody 
Workshop (342). 
4.2.4. Antibodies to the IA-2 molecule 
Antibodies to the protein tyrosine-phosphatase related IA-2 molecule (IA-2A) were 
analysed with a radiobinding assay modified from that described by Bonifacio et al. (149, 
231). The recombinant plasmid encoding the intracellular fragment of the full length IA-2 
protein, including amino acids 605-979, was transformed into E. coli JM109 cells and 
then purified by standard techniques. The IA-2 protein was produced with in vitro 
transcription and translation of the purified plasmid by the TNT
® Coupled Reticulocyte 
Lysate System (Promega, Madison, WI, USA) in the presence of 
35S-methionine 48 
(Amersham) according to the manufacturer’s instructions. Unincorporated 
35S-
methionine was removed by gel chromatography on a NAP-5 column (Pharmacia 
Biotech). Serum samples of 2 µl were incubated at +4°C overnight in 96 deep well plates 
with 10,000 cpm of labelled IA-2 protein diluted in 50 µl of TBST (50 mmol/l Tris, 150 
mmol/l NaCl, 0.1 vol/vol Tween-20, pH 7.4). Immunocomplexes were isolated by adding 
5 µl Protein-A-Sepharose CL-4B (Pharmacia Biotech) diluted in a total volume of 50 µl 
TBST to each well. After incubation for 1 hour at +4°C with shaking, the reaction 
volume was transferred to a 96-well opaque filtration plate with a 0.45 µm Durapore 
filter at the bottom of each well (Millipore, Bedford, MA, USA). The samples were 
washed 10 times with 150 µl TBST using a vacuum device (Millipore). After a short 
drying period, 10 µl of scintillation fluid (Optiphase Supermix, PerkinElmer Wallac) was 
added and the activity of the samples was measured in a liquid scintillation counter (1450 
Microbeta Trilux, PerkinElmer Wallac). All the samples were tested in duplicate. In 
addition, each plate contained a dilution series of a pool of two local positive sera diluted 
in a pool of two local negative sera. A standard curve was constructed for each plate 
using the cpm results of the dilution series (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:512 
and the pool of the two negative sera), the dilution  being assigned arbitrary values of 
100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39 and 0.1 relative units (RU), respectively. 
The standard curve was a log10/log10 curve created separately for each plate. The cut-off 
limit for positivity (0.43 RU) was set at the 99th percentile for 374 non-diabetic Finnish 
children and adolescents. The disease sensitivity of our assay was 62% and the disease 
specificity 97% based on 140 samples included in the Multiple Autoantibody Workshop 
(342). 
4.2.5. HLA typing 
HLA-A, B, C, and DR typing was performed by conventional HLA serology (344). T and 
B-lymphocytes were isolated by means of a Percoll centrifugation gradient during the 
first year of the study, and subsequently using immunomagnetic beads (Dynabeads, 
Dynal, Oslo, Norway) coated with monoclonal antibodies against either class I or class II 
antigens. The beads were added to the cooled citrated blood, and the rosettes formed 
during incubation for 5 minutes were isolated with a magnet. The rosettes were washed, 
resuspended, and then directly added to the test plate, each well of which contained 1 µl 
of well characterised HLA antiserum. 2 µl rabbit complement was added to each well 
after 20 minutes incubation at room temperature, and a mixture of acridine orange and 
ethidium bromide was added after a second incubation for 20 minutes. The reactions 
were read using a fluorescence microscope with an excitation filter of 470-490 nm after 
incubation for 15 minutes. All HLA A, B, C and DR specificities recognized by the 
Nomenclature Committee of the WHO in 1984 were included in the test panel (345).  
HLA-DQB1 alleles were defined by a previously described method based on time-
resolved fluorescence. Four sequence-specific oligonucletide probes were used to identify 
the following DQB1 alleles known to be associated with either susceptibility to or 
protection against type 1 diabetes in the Finnish population: DQB1*0302, DQB1*02, 49 
DQB1*0602 or 0603, and DQB1*0301 (47) To differentiate between DQA1*05-
DQB1*02 (DR3) and DQA1*0201-DQB1*02 (DR7) haplotypes all DQB1*02 positive 
samples were further analysed for the presence of DQA1*05 or DQA1*0201 alleles 
(346). The recently described simplified classification of DQB1 genotypes into high risk 
(DQB1*02/0302), moderate risk (DQB1*0302/x, where x stands for *0302 or a 
nondefined allele), low risk (DQB1*0301/0302, DQB1*02/0301, DQB1*02/x, 
DQB1*0302/0602-3, where x stands for *02 or a nondefined allele), and decreased risk 
(DQB1*x/x, DQB1*0301/x, DQB1*02/0602-3, DQB1*0301/0602-3, where x indicates a 
nondefined allele) genotypes was used (47). 
4.2.6. Intravenous glucose tolerance test (IVGTT) 
In paper III, IVGTTs were perfomed after a preceding fast of 10-16 hours by infusing 0.5 
g/kg glucose in a 20% solution intravenously over a period of 3 min (+/- 15 sec), and 
taking blood samples before the infusion (0 min) and 1, 3, 6, 10, 20, 30, 40, 50, and 60 
min after it had been completed. Serum insulin concentrations were determined by 
radioimmunoassay (347). The first-phase insulin response (FPIR) to glucose was defined 
as the sum of the 1 and 3 min serum insulin concentrations. The incremental 0-10 min 
and 0-60 min areas above the fasting levels for insulin were also calculated. FPIR levels 
below 46 mU/l, which corresponds to the 3rd percentile of FPIR values measured in 
healthy controls (251), were considered abnormally low. This limit was defined after 
correction for assay differences on the basis of insulin standardisation round within the 
ICA Register User Study (ICARUS). Blood glucose levels were measured by the glucose 
oxidase method (348). 
In paper V, IVGTTs were performed according to the ICARUS protocol (308). After a 
preceding 10-16 hrs fast, 0.5 g/kg glucose in a 20% solution was infused intravenously 
over a period of 3 min ±15 s. Blood samples were taken 5 and 0 minutes before the 
infusion and 1, 3, 5 and 10 minutes after the infusion had been completed. Serum insulin 
concentrations were measured with an enzyme-linked immunosorbent assay (349). The 
sensitivity of the assay was 0.5 mU/l, and the intra- and interassay coefficients of 
variation were less than 7.5% and 9.3%, respectively. Blood glucose levels were analysed 
with the glucose oxidase method (348). The first phase insulin response (FPIR) to 
glucose was defined as the sum of the 1 and 3 min serum insulin concentrations.  
4.2.7. Data handling and statistical analyses 
Student’s t-test was used to analyse normally distributed continuous variables and Mann-
Whitney U-test or Kruskall-Wallis analysis of variance in the case of skewed 
distributions. Spearman’s nonparametric correlation analysis was used to analyse the 
relationship between the levels of various antibodies. Differences in the distribution of 
individuals between groups were tested with the Chi square statistics unless any expected 50 
value was  less than five, when Fisher’s exact test was used (350). The Kaplan-Meier 
method (351) was used to construct life-tables of the likelihood of developing type 1 
diabetes. The equality of the survival distributions was tested using the log-rank test 
(352). Sensitivity is defined as the percentage of those who have the disease in whom the 
test value is positive, specificity as the proportion of those without the disease correctly 
identified by a negative test value, and PPV as the likelihood that an individual with a 
positive test will become diabetic. A two-tailed p-value of 0.05 was considered to 
indicate statistical significance. All the statistical analyses were performed using the 
SPSS statistical software package (SPSS Inc., Chicago, Illinois, USA). 
In paper III, in addition to visual analysis of the autoantibody curves from each 
individual, a summary measures approach was used to handle data from repeated 
measurements (353, 354). Six measures were created for each antibody specificity: initial 
antibody levels, peak antibody levels, time to peak antibody levels, time from peak levels 
to diagnosis, area under the antibody curve (AUC), and stability of antibodies. Area 
under the antibody curve was calculated from the equation presented by Matthews et al. 
(353). Antibody levels were considered to be unstable, if the change in antibody levels 
exceeded the interassay-variation more than two times and was higher than a defined 
minimal change in the measured units. These limits were 20% and 10 RU for IA-2A, 
24% and 10 RU for GADA, and 16% and 20 nU/ml for IAA. ICA were considered to be 
unstable if the change in ICA levels was more than one titration step. In addition, if there 
was a change from antibody positivity to antibody negativity, the levels were considered 
to be unstable. 5. Results 
5.1. Autoantibody-based risk assessment in siblings 
5.1.1. Frequency of autoantibodies 
The frequencies of ICA, IA-2A, GADA and IAA in the initial blood sample of the 755 
siblings were 7.9%, 5.3%, 7.0%, and 3.7%, respectively (Table 3). The siblings with ICA 
were significantly younger than those without these antibodies (mean age 8.8 years vs. 
10.0 years; p=0.039), whereas the levels of ICA were not related to age. The frequency or 
levels of IA-2A, GADA and IAA were not related to the age of the siblings, except for 
significantly higher levels of IAA in siblings less than 10 years of age than in the older 
ones (109 nU/ml vs. 62 nU/ml; p=0.0034). Multiple (≥2) autoantibodies were detected in 
6.2% of the siblings. Specific antibody combinations in the initial sample of all siblings 
are shown in Table 4. 
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Table 3. Islet cell antibodies (ICA), antibodies to IA-2 protein (IA-2A),  antibodies GAD65 
(GADA), insulin autoantibodies (IAA) and multiple antibodies (i.e. at least two of the 
above) in the initial blood sample from 755 siblings of children with type 1 diabetes. 
________________________________________________________________________ 
 
Antibody   Number of siblings  Median level of       
    positive for antibodies  antibodies (range) 
   (total  n=755) 
 
ICA ≥2.5 JDF units      60 (7.9%)    40 JDF units (2.5-2544) 
ICA  ≥10 JDF units    48 (6.4%)    40 JDF units (10-2544) 
ICA  ≥20 JDF units    37 (4.9%)    80 JDF units(20-2544) 
IA-2A >0.43 RU     40 (5.3%)    22.5 RU (0.49-277) 
GADA >6.5 RU      53 (7.0%)    58.1 RU (6.8-211) 
IAA  >54 nU/ml      28 (3.7%)    79 nU/ml (55-123) 
Multiple antibodies     47 (6.2%) 
________________________________________________________________________ 
 
 
 
 
Table 4.  Combinations of antibodies in the initial sample of 755 siblings. 
________________________________________________________________________ 
 
Antibody  status       n  Progression to type 1 diabetes 
         n   (%) 
 
No antibodies          661      5 (0.8) 
One antibody             47       1 (2.1) 
  ICA       17      0  
    IA-2A           5      0 
  GADA         12      1 (8.3) 
  IAA         13      0  
Two antibodies           12       3 (25.0) 
  ICA and IA-2A         2      1 (50.0) 
  ICA and GADA         6      1 (16.7) 
  ICA and IAA        1      1 (100.0) 
  IA-2A and GADA       1      0 
    GADA and IAA         2      0 
Three antibodies             30    21 (70.0) 
    ICA, IA-2A and GADA  23    16 (69.6) 
    ICA, IA-2A and IAA    3      3 (100.0) 
    ICA, GADA and IAA      3      2 (66.7) 
    IA-2A, GADA and IAA    1      0 
Four Antibodies          5      2 (40.0) 
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5.1.2. Predictive characteristics of autoantibodies 
The siblings who progressed to type 1 diabetes had more frequently ICA, IA-2A, GADA 
and IAA than those  who remained unaffected (p<0.0001 for each antibody). Life-table 
analysis showed the siblings with ICA, IA-2A, GADA or IAA in their initial blood 
sample to have a significantly higher risk of progression to type 1 diabetes than the 
antibody negative siblings (log-rank p<0.0001 for each antibody) (Fig. 1, paper I). The 
PPVs of ICA, IA-2A, GADA and IAA for progression to type 1 diabetes over 7.7 years 
were 43%, 55%, 42% and 29%, respectively. The sensitivities of ICA, IA-2A, GADA 
and IAA were 81%, 69%, 69% and 25%, respectively, and the specificities 95.3%, 
97.5%, 95.7% and 97.2%, respectively. The siblings who progressed to type 1 diabetes 
had significantly higher initial levels of ICA, IA-2A and IAA than those who remained 
unaffected, whereas the levels of GADA did not differ significantly between the groups 
(Fig. 2, paper I). Accordingly, the PPV and specificity of ICA, IA-2A and IAA increased 
and the sensitivity decreased when higher cut-off limits for positivity were used (Tables 2 
and 3, paper I). In contrast, the increase in the cut-off limit for GADA-positivity did not 
increase the PPV but reduced the sensitivity of GADA (Table 3, paper I). 
 
 
 
 
 
 
Fig. 3. Probability of remaining free of type 1 diabetes within 8 years of follow-up in relation 
to the number of autoantibodies in the initial blood sample of 755 siblings. 
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The progressors had multiple antibodies more often than the non-progressors (81.3% 
[26/32] vs. 2.9% [21/723]; p<0.00001). Life-table analysis showed the estimated risk of 
progression to type 1 diabetes in siblings with four, three, two, one or no antibodies in 
their initial blood sample to be 40%, 70%, 25%, 2% and 0.8%, respectively, over 7.7 
years (Fig. 3). When the siblings with three and four antibodies were combined, their risk 
of progression to type 1 diabetes was 66%. Accordingly, the siblings with multiple 
antibodies had an estimated risk of 55% (CI 40.1-69.8) within 7.7 years compared with a 
risk of only 0.8% in those with one or no antibodies (log-rank p<0.0001). When ICA was 
excluded from these analyses, 38 siblings (5.0%) had multiple antibodies, i.e. at least two 
of the three antibodies to biochemically defined islet antigens (IA-2A, GADA, IAA) 
(Table 4). The PPVs for three, two, one or no antibodies were 33%, 66%, 10% and 0.7%, 
respectively, and that for multiple antibodies was 61% (CI 43.4-76.0) compared to 1.3% 
(CI 0.6-2.4) for one or no antibodies (log-rank p<0.0001). The risk of developing type 1 
diabetes over 7.7 years in siblings with any of these three antibodies in their initial blood 
sample (n=76) was 35% (CI 24.9-47.3) (sensitivity 84%, specificity 93%).  
5.1.3. Associations between ICA, IA-2A and GADA 
IA-2A were detected in 33 (55.0%) of 60 ICA-positive siblings and GADA in 37 
(61.7%). Of those with ICA 10 JDF units or more 66.7%, (32/48) had IA-2A and 75.0% 
(36/48) tested positive for GADA, while of those with ICA 20 JDF units or more 78.4%, 
(29/37) had IA-2A and 83.8% (31/37) GADA. Combined screening for the presence of 
IA-2A and/or GADA identified 70% (42/60) of all the ICA-positive siblings, 85% 
(41/48) of those with ICA 10 JDF units or more and 95% (35/37) of those with ICA 20 
JDF units or more. A relatively strong positive correlation was seen between the levels of 
IA-2A and ICA (r=0.46, p<0.001), but no correlation between the levels of GADA and 
ICA (r=0.17, p=0.15) or the levels of IA-2A and GADA (r= -0.12, p=0.33). 
Life-table analysis showed the 63 siblings with IA-2A and/or GADA in their initial 
blood sample to have a 41.3% (CI 29.0-54.4) estimated risk of developing type 1 diabetes 
over 7.7 years compared with 0.9% (CI 0.3-1.9) for those testing negative for both 
antibodies in their initial sample (Log rank p<0.00001). The sensitivity of the combined 
analysis of IA-2A and GADA was 81.3% and the specificity 94.7%. Accordingly the 
predictive characteristics of a combined test for IA-2A and GADA were comparable to 
those of the ICA assay (Table 2A and Fig. 5, paper I). 55 
5.2. Combination of humoral and genetic markers in siblings 
5.2.1. Relationships between autoantibodies and genetic markers 
The prevalences of various genetic risk markers are shown in Tables 1-5 in paper II. The 
frequencies of ICA, IA-2A, GADA and IAA in the initial blood sample were 
significantly higher among the HLA-identical siblings than among the haplo- and non-
identical ones (Table 1, paper II). The HLA-identical siblings were also more often 
positive for any antibody and for multiple antibodies than the haplo- and non-identical 
ones (Table 1, paper II and Fig. 4). The levels of ICA were higher in the HLA-identical 
siblings than in haploidentical or non-identical siblings (Table 1, paper II). No significant 
differences in the levels of IA-2A, GADA or IAA were observed between the three 
groups of siblings classified according to their degree of HLA identity with the proband 
in the family. 
 
 
 
 
Fig. 4. Relation among the presence of multiple autoantibodies and HLA risk markers in 
siblings. 
*p<0.001, 
§p=0.001, 
¶p<0.05. 
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Each of the four antibody specificities analysed was found more frequently in the 
siblings with the DR4 allele than in those without that allele (Table 2, paper II). ICA and 
GADA, but not IA-2A and IAA, were more frequent in the siblings with the DR3 allele 
than in those without. Multiple antibodies were more frequent both in siblings carrying 
the DR3 allele and in siblings with the DR4 allele than in those lacking such alleles. The 
siblings carrying the DR2 allele tested less often positive for ICA, IA-2A, GADA, any 
antibody and multiple antibodies than the other siblings. The levels of ICA were higher in 
the DR4-positive siblings than in the DR4-negative ones (median 40 JDF units [range 3-
640 JDF units] vs. 10 JDF units [range 5-80 JDF units], p=0.032), whereas no significant 
differences in ICA levels were observed between those who were positive and negative 
for DR3 or DR2 (data not shown). The levels of IA-2A, GADA and IAA did not differ 
significantly between the siblings who were positive and negative for DR3, DR4 or DR2 
(data not shown). 
The frequencies of single antibody specificities, any antibody and multiple antibodies 
were significantly higher in DR3/4 heterozygous siblings than in the siblings with any 
other DR phenotype (Table 3, paper II and Fig. 4). Among the antibody positive siblings 
the levels of ICA, IA-2A, GADA and IAA did not differ significantly between subjects 
with different DR phenotypes (Table 3, paper II).  
Siblings carrying the DQB1*0302 allele had ICA, IA-2A, GADA, IAA, any antibody 
and multiple antibodies more often than those without this allele (Table 2, paper II). The 
siblings with the DQB1*02 allele tested positive for GADA and multiple antibodies 
significantly more often than those without the DQB1*02 allele, but not for ICA, IAA or 
IA-2A. The frequencies of ICA, IA-2A, GADA and multiple antibodies, but not IAA, 
were significantly lower in the siblings carrying the DQB1*0602-3 allele than in the 
other siblings. The levels of ICA were higher in the siblings carrying the DQB1*0302 
allele than in those without this allele (median 40 JDF units [range 3-640 JDF units] vs. 
10 JDF units [range 3-80 JDF units], p=0.010), but no significant differences in ICA 
levels were found between those who were positive and negative for DQB1*02 or 
DQB1*0602-3 (data not shown). There was a tendency for higher levels of IA-2A in the 
siblings with the DQB1*0302 allele than in those without this allele (median 44.9 RU 
[range 0.49-277.1 RU] vs. 5.7 RU [range0.58-61.9 RU], p=0.055). There was no 
difference in the levels of IA-2A between the siblings with and without the DQB1*02 or 
DQB1*0602-3 allele (data not shown). The levels of GADA and IAA did not differ 
significantly between the siblings who were positive and negative for the DQB1*0302, 
DQB1*02 or DQB1*0602-3 alleles (data not shown). 
The prevalence of antibodies in siblings with specific DQB1 genotypes is shown in 
Table 4 in paper II. The highest frequency of all antibodies was seen in the siblings with 
DQB1*02/0302, and the second highest prevalence in those with the DQB1*0302/x 
genotype, although antibodies (one or more) were also present in siblings with other 
specific genotypes. According to the simplified classification of DQB1 conferred genetic 
risk, the proportions of subjects testing positive for ICA, IA-2A, GADA, IAA, any 
antibody and multiple antibodies were higher among the siblings with the high risk 
genotype than among those with the other DQB1 genotypes (Table 5, paper II and Fig. 4), 
although the differences were not significant between those with the high risk and those 
with the moderate risk genotype. There were no significant differences in the frequencies 
of antibodies between any specific genotypes within the moderate, low or decreased risk 57 
groups. The levels of ICA were significantly lower in the siblings with the decreased risk 
genotype than in those with the high risk, moderate risk or low risk genotypes (Table 5, 
paper II). The levels of IA-2A, GADA and IAA did not differ significantly between the 
risk groups. 
5.2.2. Predictive characteristics 
Survival analysis showed the HLA-identical siblings, the DR3/4 heterozygous siblings 
and those carrying the HLA DQB1*02/0302 genotype to have a significantly higher risk 
of contracting clinical disease over the follow-up period of 8.9 years than did the 
haploidentical and non-identical siblings, those with other DR phenotypes and those with 
other DQB1 genotypes, respectively (Table 6, paper II). The HLA identical siblings 
positive for ICA, IA-2A, GADA, IAA, any antibody or multiple antibodies, progressed to 
type 1 diabetes more often than did the haplo- and non-identical subjects. The risk of 
clinical disease was also higher in the DR3/4 heterozygous siblings who were positive for 
any antibody than in those with other DR genotypes, but no significant differences were 
observed between the DR3/4 heterozygous and other siblings who were positive for any 
single antibody specificity or multiple antibodies. Similarly, the siblings testing positive 
for ICA or any antibody in combination with the DQB1*02/0302 genotype had higher 
risk of type 1 diabetes than those with other DQB1 genotypes, whereas no differences 
were found among siblings positive for other antibody specificities or multiple 
antibodies.  
The PPVs and sensitivities of the autoantibodies, high risk genetic markers and 
combinations of these markers are summarized in Table 5. IA-2A and multiple antibodies 
had the highest PPVs (56.8%). As a single genetic marker, the HLA DQB1*02/0302 
genotype had the highest PPV (22.2%). Positivity for any antibody, ICA and multiple 
antibodies had the highest sensitivities (81.8%, 78.8% and 75.8%, respectively). The 
sensitivity of increased DQB1 defined risk, ie. the combination of the siblings with high, 
moderate and low genetic risk, was high (96.8%), since the six antibody-negative 
progressors were also identified by this measure (Fig. 5). However, the PPV and the 
specificity of this combination were low, only 8.6% and 40.4% respectively. The 
combination of HLA identity, DR3/4 heterozygosity or the DQB1*02/0302 genotype and 
autoantibodies increased the PPVs of all humoral markers, but reduced the sensitivities 
considerably at the same time. This is illustrated for ICA as a survival plot in Fig. 3 in 
paper II. The DQB1*02/0302 genotype in combination with IA-2A had the highest PPV 
(77.8%), but its sensitivity was only 22.6%. 
The risk of progression to type 1 diabetes was related to the number of antibodies 
(Table 6). The PPV was highest for the presence of three antibodies (74.1%) and was 
further increased by combining this with HLA identity, the DR 3/4 phenotype or 
DQB1*02/0302 genotype (80.0%, 100% and 100%, respectively). As for single antibody 
markers, this also reduced the sensitivity at the same time. No specific antibody 
combination had PPVs significantly different than the others. 58 
Table 5. Positive predictive value and sensitivity of autoantibodies and genetic markers 
for progression to type 1 diabetes over 8.9 years in siblings of children with type 1 
diabetes. 
 
Antibody and genetic marker  PPV  Sensitivity 
ICA  45.6% (CI 32.4-59.3)  78.8% 
IA-2A  56.8% (CI 39.5-72.9)  63.6% 
GADA  42.0% (CI 28.2-56.8)  63.6% 
IAA  30.8% (CI 14.3-51.8)  24.2% 
Any antibody  30.3% (CI 21.0-41.0)  81.8% 
Multiple antibodies  56.8% (CI 41.0-71.7)  75.8% 
    
HLA identical  11.9% (CI 7.5-17.6)  63.6% 
HLA DR3/4  18.9% (CI 9.4-32.0)  30.3% 
HLA DQB1*0201/0302  22.2% (CI 12.0-35.6)  38.7% 
    
HLA identical + ICA  73.9% (CI 51.6-89.9)  51.5% 
HLA identical + IA-2A  73.7% (CI 48.8-90.9)  42.4% 
HLA identical + GADA  56.0% (CI 34.9-75.6)  42.4% 
HLA identical + IAA  50.0% (CI 21.9-78.9)  18.2% 
HLA identical + any antibody  54.5% (CI 36.4-71.9)  54.5% 
HLA identical + multiple antibodies  68.0% (CI 46.5-85.1)  51.5% 
    
HLA DR3/4 + ICA  66.7% (CI 34.9-90.1)  24.2% 
HLA DR 3/4 + IA-2A  70.0% (CI 34.8-93.3)  21.2% 
HLA DR3/4 + GADA  57.1% (CI 28.9-82.3)  24.2% 
HLA DR3/4 + IAA  25.0% (CI 0.6-80.6)  3.0% 
HLA DR3/4 + any antibody  53.3% (CI 26.6-78.7)  24.2% 
HLA DR3/4 + multiple antibodies  61.5% (CI 31.6-86.1)  24.2% 
    
DQB1*02/0302 + ICA  75.0% (CI 42.8-94.5)  29.0% 
DQB1*02/0302 + IA-2A  77.8% (CI 40.0-97.2)  22.6% 
DQB1*02/0302 + GADA  61.5% (CI 31.6-86.1)  25.8% 
DQB1*02/0302 + IAA  40.0% (CI 5.3-85.3)  6.5% 
DQB1*02/0302 + any antibody  56.3% (CI 29.9-80.2)  29.0% 
DQB1*02/0302 + multiple antibodies  69.3% (CI 38.6-90.9)  29.0% 
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Table 6. Positive predictive value and sensitivity of the number of autoantibodies positive 
combined with genetic markers for progression to type 1 diabetes over 8.9 years in 
siblings of children with type 1 diabetes. 
Antibody and genetic marker  PPV  Sensitivity 
No antibodies  1.0%   (6/612)  18.2% 
One antibody  4.4%   (2/45)  6.1% 
Two antibodies  25.0% (3/12)  9.1% 
Three antibodies  74.1% (20/27)  60.6% 
Four antibodies  40.0% (2/5)  6.1% 
    
HLA identical +  No antibodies  2.1%   (3/144)  9.1% 
HLA identical + One antibody  12.5% (1/8)  3.0% 
HLA identical + Two antibodies  42.9% (3/7)  9.1% 
HLA identical + Three antibodies  80.0% (12/15)  36.4% 
HLA identical + Four antibodies  66.7% (2/3)  6.1% 
    
HLA DR 3/4 + No antibodies  5.3%   (2/38)  6.1% 
HLA DR3/4 + One antibody  0%      (0/2)  0% 
HLA DR3/4 + Two antibodies  0%      (0/3)  0% 
HLA DR3/4 + Three antibodies  100%  (8/8)  24.2% 
HLA DR3/4 + Four antibodies  0%      (0/2)  0% 
    
DQB1*02/0302 + No antibodies  7.9%   (3/38)  9.7% 
DQB1*02/0302 + One antibody  0%      (0/3)  0% 
DQB1*02/0302 + Two antibodies  25%    (1/4)  3.2% 
DQB1*02/0302 + Three antibodies  100%  (8/8)  25.8% 
DQB1*02/0302 + Four antibodies  0%      (0/1)  0% 
 
Fig. 5. DQB1-defined genetic risk, number of autoantibodies, and progression to type 1 
diabetes in 565 siblings. 
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5.3. Characterisation of preclinical type 1 diabetes 
5.3.1. Clinical and genetic characteristics  
Nineteen progressors (49%) were boys and 20 girls. The mean age was 7.6 years (range 
0-16.4 years) at the time of initial screening and 12.0 years (range 1.5-28.1 years) at the 
time of diagnosis. The median time from initial blood sampling to the diagnosis of type 1 
diabetes was 4.3 years (range 0.02-11.7 years). The progressors were more often HLA-
identical with the diabetic proband in the family than the 39 non-progressors (Table 1, 
paper III). In addition, they carried more often the DQB1*02 and DQB1*0302 risk alleles 
and the high risk DQB1*02/0302 genotype, while only one progressor carried a 
decreased risk genotype.  
5.3.2. Autoantibody profiles 
There was no general pattern in the course of any antibody specificity either in the whole 
study group or between progressors and non-progressors. This major observation is 
illustrated as the temporal profile of autoantibodies in ten representative progressors in 
Fig. 6A and in ten representative non-progressors in Fig. 6B.  
Six progressors (15%) tested negative for all four antibody specificities at the time of 
initial screening. One or more of the antibodies emerged in five of them during the 
follow-up, while the remaining subject had no follow-up samples available for antibody 
measurements. The sequential order of appearance of antibodies varied between these 
individuals. All four types of antibodies emerged in 26 (68%) of those 38 progressors 
with follow-up samples available during the preclinical period. In the remaining 12 
subjects autoantibodies were detected in different combinations. Only one progressor did 
not have multiple (≥2) autoantibodies, since only IAA were detected in his samples, 
although the last sample was obtained 3.8 years before the diagnosis (sibling #10 in Fig. 
6A). Among the non-progressors, all four antibodies emerged in nine subjects during the 
follow-up (23%; P=0.0001 vs. progressors). 
The initial and peak levels of all antibodies and the time point when the levels peaked 
during the follow-up varied widely between individuals, both among the progressors and 
non-progressors (Table 2, paper III). The initial and peak levels of ICA were significantly 
higher in the progressors than in those who had remained unaffected, whereas no such 
differences were observed for IA-2A, GADA or IAA. In the progressors, peak levels of 
ICA, IA-2A, GADA and IAA were detected in the initial serum sample in 14%, 24%, 
26% and 10% of the cases, respectively, whereas 22%, 24%, 29% and 28% of the cases 
had their peak levels close to the time of diagnosis, respectively. There was no correlation 
between the initial or peak levels of any antibody and the length of the preclinical phase 
or age at diagnosis. Neither did the initial or peak antibody levels differ significantly 
between boys and girls, nor was there any correlation between the age at initial screening 
and the initial or peak antibody levels among the progressors or non-progressors.  61 
Twenty-three percent, 12%, 24% and 9% of the progressors had stable levels of ICA, 
IA-2A, GADA or IAA during the follow-up, respectively, and the corresponding figures 
for non-progressors were 28, 10, 44 and 0 percent, respectively, the difference between 
the two groups being nonsignificant. The frequency of stable antibody levels was not 
related to age, sex or specific DQB1 alleles or genotypes. Total quantity of ICA, 
measured by area under the curve (AUC), was significantly higher in the progressors than 
in the non-progressors, whereas there were no significant differences in total quantity of 
any other antibody specificity (Table 2, paper III). AUC of antibodies were unrelated to 
age and sex.  
5.3.3. First-phase insulin response (FPIR) 
One or more intravenous glucose tolerance tests (IVGTT) were performed during the 
follow-up in 25 progressors and in 25 non-progressors. The initial, minimum and 
maximum FPIRs were significantly lower in progressors than in the non-progressors 
(Table 1, paper III). Among the progressors, 18 siblings had an abnormally low (<46 
mU/l) first phase insulin response (FPIR) on one or more occasions. The number of 
IVGTTs was, however, limited or they were performed long before the diagnosis (>6 
months) in four of the remaining seven subjects. Seventeen of these 18 progressors had 
multiple autoantibodies (i.e. two or more) at the time of the first reduced FPIR, and the 
remaining sibling had also tested positive for multiple antibodies in earlier samples. In 
addition, the levels of one or more of these antibodies were high in these siblings at the 
time of reduced FPIRs (e.g. siblings 1, 3, 5 and 6 in Fig. 6A). On the other hand, there 
were four progressors with persistently moderate or high levels of multiple 
autoantibodies still having normal FPIRs during the follow-up (e.g. siblings 7 and 9 in 
Fig. 6A). The longest time from the first low FPIR to the diagnosis of type 1 diabetes was 
5.8 years, and seven siblings had their first low FPIR more than 2 years before the 
diagnosis. On the other hand, three siblings had the last normal FPIR less than half a year 
before the diagnosis. Among the non-progressors, four siblings had a decreased FPIR on 
one or more occasions. All of these siblings had high levels of multiple antibodies during 
the follow-up. In one of them, the FPIR recovered to normal values during follow-up 
(sibling 1 in Fig. 6B).  
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Fig. 6A. Temporal profiles of autoantibodies in siblings of children with type 1 diabetes 
during prospective follow-up. Ten representative siblings who have progressed to type 1 
diabetes (Panel A). The length of follow-up in years is shown on the x-axis. ICA in JDF units, 
line with triangles; IA-2A in relative units, line with rhombs; GADA in relative units, line 
with circles; IAA in nU/ml, line with squares. Open symbols indicate antibody-negative and 
closed symbols antibody-positive samples. Arrow indicates time of diagnosis of type 1 
diabetes. Rhombs indicate first phase insulin response (FPIR) to intravenous glucose and the 
values are shown above the rhombs (mU/l); open rhombs indicate FPIR in normal range and 
closed rhombs FPIR below the normal range (46 mU/l). 
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Fig. 6B. Temporal profiles of autoantibodies in siblings of children with type 1 diabetes 
during prospective follow-up. Ten representative siblings who have remained unaffected. The 
length of follow-up in years is shown on the x-axis. ICA in JDF units, line with triangles; IA-
2A in relative units, line with rhombs; GADA in relative units, line with circles; IAA in 
nU/ml, line with squares. Open symbols indicate antibody-negative and closed symbols 
antibody-positive samples. Arrow indicates the length of follow-up. Rhombs indicate first 
phase insulin response (FPIR) to intravenous glucose and the values are shown above the 
rhombs (mU/l); open rhombs indicate FPIR in normal range and closed rhombs FPIR below 
the normal range (46 mU/l). 
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5.4. Autoantibodies, genetic risk markers and FPIR in schoolchildren 
5.4.1. Autoantibodies 
The frequency and levels of autoantibodies in 3652 healthy Finnish schoolchildren are 
shown in Fig. 1 in paper IV, and in Table 7. The distribution of specific autoantibody 
combinations is shown in Fig 7. Subjects with IA-2A and multiple antibodies were 
younger than those negative for IA-2A and those with one or no antibodies, respectively 
(mean age 10.4 years vs. 11.7 years, P=0.013, and mean age 10.5 years vs. 11.7 years, 
P=0.023). Other antibodies were not related to age.  
 
 
Table 7. Frequency of ICA, IA-2A, GADA, IAA, any antibody (i.e. one or more) and 
multiple antibodies (i.e. two or more) in 3652 healthy Finnish schoolchildren. 
 
Antibody Number  of  positive 
subjects (total n=3652) 
Median level 
of antibodies 
Range 
      
ICA ≥2.5 JDF units  102 (2.8%)  6 JDF units  4-514 JDF units 
ICA ≥10 JDF units  49 (1.3%)  18 JDF units  10-514 JDF units 
ICA ≥20 JDF units  14 (0.4%)  34 JDF units  34-514 JDF units 
ICA ≥40 JDF units  6 (0.2%)  98 JDF units  66-514 JDF units 
IA-2A ≥0.43 RU  21 (0.6%)  3.48 RU  0.49-112 RU 
GADA ≥6.6 RU  19 (0.5%)  49 RU  7.2-114 RU 
IAA ≥1.56 RU  34 (0.9%)  4.47 RU  1.88-155 RU 
Any antibody  141 (3.9%)     
Multiple antibodies  21 (0.6%)     
 
 
The distribution of the specific antibody combinations in initial and follow-up samples 
of 104 initially ICA and/or GADA positive children is shown in Fig 8. The mean time 
interval between the first and second serum samples was 1.9 years (range 1.7-2.2 years). 
Only three out of the 98 (3.1%) subjects initially positive for ICA tested negative in the 
follow-up sample. Correspondingly, 3/13 (23.1%) initially IA-2A-positive subjects turned 
negative for IA-2A, whereas only 1/17 (5.9%) initially GADA-positive subjects 
converted to GADA negativity in the follow-up sample. Two of the seven children 
(28.6%) who initially tested positive for IAA, turned IAA-negative. One out of the 104 
initially antibody-negative control children tested antibody-positive in the follow-up 
sample. This girl had an ICA level of 18 JDF-units, but remained negative for the other 
antibody specificities. 
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Fig. 7. The distribution autoantibodies in unaffected Finnish schoolchildren. Data are number 
of subjects. "%" indicates the proportion of subjects of all 144 autoantibody positive subjects. 
 
 
Fig. 8. Distribution of ICA, IA-2A, GADA and IAA in the initial and follow-up samples of 104 
non-diabetic Finnish schoolchildren initially tested for ICA and GADA. Numbers of subjects 
are presented, and the arrows indicate change from one group to another between the initial 
and follow-up samples. 
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5.4.2. Relation between autoantibodies and HLA-DQB1 risk markers 
The distribution of DQB1 genotypes differed significantly between the GADA-positive 
schoolchildren and antibody-negative control children (P=0.001) (Fig. 3, paper IV), and 
the GADA-positive children had more often the high risk DQB1*02/0302 genotype than 
the control children (Table 2, paper IV). Also, the DQB1*0302 allele was more 
frequently present in GADA-positive children and the DQB1*0602 or *0603 allele was 
less prevalent in GADA-positive subjects. There were no specific associations between 
ICA (≥2.5, ≥10 or ≥20 JDF units) and DQB1 alleles or genotypes, except for a higher 
frequency of the DQA1*05-DQB1*02 haplotype in subjects with ICA ≥2.5 JDF units 
(Table 3, paper IV). No specific associations were observed between IA-2A or IAA and 
DQB1 alleles or genotypes (Table 2, paper IV). Among the antibody-positive children, 
the levels of ICA, IA-2A, GADA or IAA did not differ significantly between the subjects 
who were positive or negative for the DQB1*0302, DQB1*02 or DQB1*0602 or *0603 
alleles or between subjects with various DQB1 risk genotypes (data not shown). 
The distribution of DQB1 genotypes differed also significantly between the children 
with and without multiple autoantibodies (p=0.009) (Fig. 3, paper IV), and the 
DQB1*02/0302 genotype was more common in the children with multiple antibodies 
than in those with one or no antibodies (p=0.041) (Table 3, paper IV). The DQB1*0302 
allele was also more frequent in those with multiple antibodies (p=0.010).  
Four children had three and five had all four antibody specificities in their serum 
sample (Fig. 7). Altogether, five of these nine subjects (56%) were positive for the 
DQB1*0302 allele, but none carried the high risk DQB1*02/0302 genotype. Two 
subjects were positive for the DQB1*02 allele, two for the DQB1*0301 allele and three 
for the DQB1*0602 or *0603 allele.  
5.4.4. Beta-cell function, autoantibodies and HLA-DQB1 risk 
markers  
The FPIRs did not differ significantly between the antibody positive subjects and control 
children, as shown in Table 2 and Fig 2 in paper V. Similarly, the FPIRs did not differ 
significantly between the ICA-positive and control children, even if only those with an 
ICA level of ≥10 JDF units (median FPIR 81 mU/l), those with ≥20 JDF units (median 
FPIR 70 mU/l), or those with ≥40 JDF units (median FPIR 71 mU/l) were compared to 
the control children. In contrast, the subjects with IA-2A, GADA, IAA or multiple 
antibodies in their initial blood sample had significantly lower FPIRs than the control 
children (p=0.033, p=0.027, p=0.01 and p=0.048, respectively). There was no significant 
correlation between age and FPIR either among the antibody-positive children or among 
the control children (rs=0.074 and 0.124, respectively). 
There were no significant differences in the FPIR between subjects with and without 
the DQB1*02, DQB1*0302, DQB1*0301 or DQB1*0602-3 allele, nor between those 
with and without the DQB1*02/0302, DQB1*0302/x or DQB1*02/x  ("x" indicates 
unrecognized allele or homozygosity for a marked allele) genotype (data not shown). 67 
These results remained nonsignificant irrespective of whether the control subjects were or 
were not included in the analysis. 
Altogether, six (5.8%) initially antibody-positive subjects had a FPIR value below the 
1
st percentile of the FPIR values seen in the control children (<29.5 mU/l). The 
characteristics of these children are shown in Table 3 in paper V. Three of them had 
multiple antibodies. None of these six children carried a DQB1 genotype associated with 
increased risk of progression to type 1 diabetes, whereas three of them carried the 
DQB1*0602 or *0603 allele conferring decreased risk. 
5.4.3. Progression and nonprogression to type 1 diabetes 
Four children out of all 3652 schoolchildren (0.11%) progressed to type 1 diabetes over a 
median follow-up of 5.3 years (range 5.2-5.5 years). The characteristics of these children 
are shown in Table 4 in paper IV. All progressors had multiple antibodies in their initial 
blood sample. The PPVs and sensitivities of ICA, IA-2A, IAA and GADA for 
progression to type 1 diabetes within 5.3 years are shown in Table 8. The PPVs were 
highest for ICA ≥20 JDF units (29%) and for ICA ≥40 JDF units (50%), the former 
having a sensitivity of 100% and the latter of 75%. Sensitivities of ICA ≥2.5, IA-2A, any 
antibody and multiple antibodies were also 100%, while the sensitivity of GADA was the 
lowest (50%). None of the progressors carried the high risk DQB1*02/0302 genotype, 
nor the DQB1*0302 allele. Two subjects carried the DQA1*05-DQB1*02 haplotype, one 
of them being homozygous and the other having also the protective DQB1*0602 allele. 
One progressor carried the DQB1*x/x genotype, and one carried the protective 
DQB1*0301/0603 genotype. An IVGTT was performed at the time of the second sample 
in two progressors, 2.7 and 1.4 years before the diagnosis (Subject #2 and 3 in Table 3, 
paper V). Both of them had FPIR values under the 1
st percentile (10.5 and 26.2 mU/l). 
 
 
Table 8. Positive predictive value (PPV) and sensitivity of autoantibodies for progression 
to type 1 diabetes over 5.3 years of follow-up in 3652 unaffected Finnish schoolchildren. 
 
Antibody PPV  Sensitivity 
ICA ≥2.5 JDF units  3.9%  100% 
ICA ≥10 JDF units  8.2%  100% 
ICA ≥20 JDF units  28.6%  100% 
ICA ≥40 JDF units  50.0%  75% 
IA-2A ≥0.43 RU  19.0%  100% 
GADA ≥6.6 RU  10.5%  50% 
IAA ≥1.56 RU  8.8%  75% 
Any antibody  2.8%  100% 
Multiple antibodies  19.0%  100% 
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Seventeen (81%) of the 21 children with multiple antibodies did not progress to type 1 
diabetes. The progressors were significantly younger at initial screening [median 8.8 
years (6.9-9.1 years) vs. 10.8 years (7.8-15.1), p=0.009] and had significantly higher 
initial levels of ICA than the non-progressors [median 98 JDF units (34-258 JDF units) 
vs. 18 JDF units (0-514 JDF units), p=0.024]. The levels of IAA and IA-2A were also 
higher in the progressors, although the differences remained nonsignificant (p=0.203 and 
p=0.123, respectively; data not shown). The frequency of specific DQB1 alleles or 
genotypes or the number of reported infections over the preceding 12 months did not 
differ between the progressors and the non-progressors (data not shown). 6. Discussion 
6.1. Risk assessment strategies for siblings 
The major goal of research into type 1 diabetes is its prevention and one prerequisite for 
this is the identification of those individuals who will later progress to clinical disease. 
Autoantibodies and genetic markers have proved to be of major use in this respect. None 
of these markers seems to be capable of identifying all progressors, however, and vice 
versa, not all subjects with these risk markers progress to overt type 1 diabetes. Along 
with accumulating data on the possibilities for preventing the disease, there is an urgent 
need to define predictive strategies for various target populations. Siblings of children 
with type 1 diabetes form a special group of high-risk individuals and are currently 
commonly recruited for follow-up studies and intervention trials. Although a series of 
studies have been published describing the predictive characteristics of autoantibodies 
(e.g. 276, 286, 288), the present work was the first to evaluate all four major disease-
associated autoantibodies in a large unselected population-based series of siblings. 
Furthermore, there has been a scarcity of data describing the relationships between 
autoantibodies and various genetic risk markers and their combined utility for the 
prediction of type 1 diabetes in siblings. From a practical point of view, the most urgent 
moment for evaluating the risk of future type 1 diabetes would be at the time when the 
first child in the family presents with the disease. In the series reported here, the initial 
blood samples were taken at or close to the time of diagnosis of the diabetic proband, 
which has not been the case in previous investigations. Accordingly this study allows a 
non-biased view for defining the risk assessment strategies for use with siblings of 
children with type 1 diabetes. 
Some variation exists in the reported frequencies of ICA, IA-2A, GADA and IAA in 
siblings, although the varying detection thresholds for positivity and other 
methodological differences make it difficult to compare such results directly. The present 
results and other reports nevertheless suggest that the frequency of autoantibodies is 
higher than that of the disease itself, even among first-degree relatives. Increased 
prevalences of antibodies were observed here to be closely associated with HLA identity, 
the DR4 and DQB1*0302 alleles and the DR3/4 phenotype and DQB1*02/0302 70 
genotype. GADA were associated with the DR3 and DQB1*02 alleles, as has been 
reported elsewhere (229, 257). By contrast, siblings carrying the protective DR2 or 
DQB1*0602-3 allele had a lower frequency of autoantibodies than the others. These 
results show that the high-risk HLA markers are closely associated with autoantibodies, 
and that both the DR2 and DQB1*0602-3 alleles are not only associated with a low risk 
of clinical disease (37-39, 45, 299) but also with partial protection from disease-
associated humoral autoimmunity. 
All four antibodies were shown to be useful individual markers for predicting type 1 
diabetes in siblings. ICA was the most sensitive (81%), while IA-2A had the highest PPV 
for the development of type 1 diabetes over a period of 8 years. Among the genetic 
markers, DQB1*02/0302 had the highest PPV (22%), while HLA identity to the diabetic 
proband had the highest sensitivity (64%). The use of different thresholds for antibody 
positivity has been shown to alter the PPV and sensitivity of ICA (274), and this finding 
was confirmed here and was also observed for IA-2A and IAA. By contrast, the initial 
levels of GADA were not related to the risk of type 1 diabetes, and therefore an increase 
in the cut-off limit for positivity did not increase the PPV of GADA but markedly 
reduced the sensitivity. Accordingly, quantification of the initial levels of ICA, IA-2A and 
IAA would help to increase the accuracy of the prediction, whereas GADA may be of no 
use in this respect. Another approach increasing the accuracy of the prediction in siblings 
was to combine humoral and genetic risk markers. We observed here that the 
combination of these markers increased the PPVs of all the autoantibodies substantially. 
On the other hand, like an increase in the threshold for antibody positivity, this also 
resulted in a substantial decrease in sensitivity. These two approaches may therefore have 
clinical impact only when the risk of progression to type 1 diabetes is being evaluated at 
the individual level or when those at high risk are being recruited for intervention trials. 
Although no specific risk genotype increased the sensitivity of the screening, the 
combination of siblings with increased DQB1 defined genetic risk revealed a sensitivity 
of 97%. This combination had a low specificity, however, and a positive predictive value 
of less than 10%. From a practical point of view, such a screening strategy would require 
the observation of an extensive sibling population, a minority of whom would progress to 
type 1 diabetes. Accordingly, the use of autoantibodies alone can be recommended when 
aiming at a sensitive screening method with optimal specificity in order to identify the 
majority of future progressors among siblings. 
The presence of multiple antibodies has been shown to result in higher predictive 
values for type 1 diabetes progression than does single antibody positivity (149, 276, 279, 
293). The populations on which this observation was based were relatively small and 
selected, however (149, 276, 293), or else the follow-up of the unselected relatives was 
short (279). In the present survey around 6% of the siblings were observed to have 
multiple antibodies in their initial blood sample, and these had a 55% estimated risk of 
contracting type 1 diabetes within 8 years (sensitivity 81%, specificity 97.0%) compared 
with only 0.8% in those with one or no antibodies. Verge et al. (279) also report that the 
risk of type 1 diabetes increases with the number of detectable autoantibodies, and that 
relatives with three autoantibodies (IA-2A, GADA and IAA) in their series had a 100% 
estimated risk of contracting type 1 diabetes within 5 years. Interestingly, only two of our 
six siblings with antibodies to these all three biochemically characterised antigens 
presented with clinical type 1 diabetes. On the other hand, the presence of only one of 71 
these three antibodies did not rule out progression to the clinical disease, since four 
progressors had only one antibody initially (two had GADA, one IA-2A and one IAA). 
The combination of high-risk genetic markers and the presence of multiple antibodies 
further increased the PPVs to close to 70%, but also yielded a poor sensitivity of only 
approximately 30%. Even higher PPVs were achieved when the number of antibodies 
was taken into account, as the siblings with the DR3/4 phenotype or the DQB1*02/0302 
genotype and three antibodies had a 100% risk of developing the disease over 9 years. All 
in all, the number of autoantibodies detected at the time of initial screening is closely 
related to the subsequent risk of type 1 diabetes, and should be considered when grading 
the siblings into risk groups. 
The data from the present series of siblings enable a specific risk assessment strategy 
to be presented (Fig. 9). The initial screening for autoantibodies would commence in 
siblings less than 20 years of age at the time when the first child in the family is 
diagnosed as having clinical type 1 diabetes, and all siblings born subsequently should 
also be screened, e.g. at the age of one year. The first step would include testing for IA-
2A, GADA and IAA, since our data support the view that combined evaluation of these 
autoantibodies can replace the relatively laborious histochemical ICA test as the first-step 
screening in siblings. Furthermore, along with advances in the development of simple, 
high quality assays for these biochemically characterised autoantigens, this procedure 
offers a feasible and effective strategy due to its high throughput capacity and small 
sample volume requirements. The first step would yield the maximum sensitivity that can 
be achieved by testing for autoantibodies at a single time point (~85%). Ten percent of 
the siblings are identified as testing positive for autoantibodies at the first step, and these 
would further be tested for ICA and typed for HLA-DQB1 genotypes at the second step. 
Based on the results of steps one and two, the risk of progression to type 1 diabetes 
within the next 10 years can be defined, varying from less than 5% to 90%. It should be 
noted, however, that no reasonable risk assessment strategy could be established that 
would identify all individuals who progress to type 1 diabetes. Only screening all siblings 
for autoantibodies and HLA-markers and subsequent extensive follow-up of antibody-
negative siblings for the emergence of autoantibodies would yield a sensitivity close to 
100%. This kind of strategy would be laborious, would reduce the cost-effectiveness and 
specificity of the screening programme, and would result in complicated predictive 
measures. 
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Fig 9. A proposal for a two-step screening strategy for estimating the risk of progression to 
type 1 diabetes over the next 10 years for initially unaffected siblings of children with type 1 
diabetes. The first step would commence at the time of diagnosis of type 1 diabetes in the first 
child in the family and include all siblings less than 20 years of age. All newborn siblings 
thereafter would also be screened e.g. at the age of one year. All siblings positive for one or 
more autoantibodies at the first step would further be tested for ICA and their HLA-DQB1 is 
defined. 
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All autoantibody-positive siblings (~10%) 
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6.2. Characterisation of preclinical beta-cell autoimmunity 
Although the autoimmune nature of progressive beta-cell destruction has been known for 
more than twenty years, there is still no consensus regarding the course of the preclinical 
disease process. Some studies indicate a linear decline in beta-cell function and mass 
(252), while others suggest a less predictable non-linear destructive process with 
fluctuating autoimmunity and beta-cell function (253-255). The present work represents 
the first attempt to characterise the course of preclinical abnormalities prospectively in a 
large series of initially unaffected subjects.  
The age at diagnosis and the duration of the known asymptomatic preclinical period 
with signs of beta-cell autoimmunity varied widely in this series. In most cases 
autoantibodies were detected at the time of initial screening, indicating that the 
autoimmune process had started earlier. These findings are in line with those obtained 
elsewhere (254, 266), and clearly support the concept of slowly progressive 
autoimmunity in a majority of cases (267, 355). All but one of the progressors carried one 
or both of the DQB1*02 and DQB1*0302 risk alleles, confirming their major 
contribution to disease susceptibility in siblings. These alleles were also frequent in the 
non-progressors, however. Furthermore, 34% of the progressors were either HLA 
haploidentical or non-identical to the diabetic proband in the family, suggesting either 
heterogeneity in genetic susceptibility within the family, an additional contribution of 
non-HLA genes to disease susceptibility, or the effect of shared environmental factors in 
these families. 
Multiple autoantibodies against the endocrine pancreas were detected in virtually all 
the siblings who progressed to clinical type 1 diabetes during the follow-up, the two 
exceptions having their last samples taken several years before diagnosis. The number, 
order of appearance and temporal profile of the autoantibodies varied widely between 
individuals, however. Moreover, a similar wide individual variation in these measures 
was observed in the siblings who did not progress to overt disease within 10 years of 
follow-up. None of the present variables was pathognomonic for disease progression and 
none of them could clearly distinguish the progressors from the non-progressors. Even 
the presence of all four antibodies during the follow-up did not inevitably indicate 
progression to clinical disease, since a considerable proportion of the non-progressors 
(~25%) presented with all of them. It should be noted, however, that it is not known 
whether or not the beta-cell autoimmunity detected in the present non-progressors will 
ultimately lead to clinical presentation with type 1 diabetes later in life, as recently 
suggested (266). In any case, the present results imply extensive heterogeneity in the 
natural course of beta-cell autoimmunity. In some individuals the preclinical autoimmune 
process seems to be active and dynamic, as recently observed in young offspring of 
parents with type 1 diabetes (255), whereas in others there are few changes in the 
dynamic pattern of humoral autoimmunity with time.  
A reduced first phase insulin response to intravenous glucose has been shown to 
indicate a high risk of rapid progression to overt diabetes in ICA-positive first-degree 
relatives of patients with type 1 diabetes (310). The present results demonstrate, however, 
that the rate of decrease in beta-cell function before clinical manifestation of the disease 
varies widely between individuals. A reduced FPIR was closely associated with signs of 74 
extensive humoral autoimmunity against beta-cell structures, since all progressors with 
impaired beta-cell function had multiple autoantibodies with high titres, obviously 
reflecting aggressive destruction of beta cells. The titres of these antibodies did not 
predict the rate of decrease in beta-cell function, however, since some cases with 
persistently high titres of multiple autoantibodies over several years still had their FPIR 
within the normal range. 
6.3. Risk assessment strategies for the general population 
Since almost 90% of new onset patients have no first-degree relatives with type 1 
diabetes (338, 356), it is reasonable to establish effective risk assessment strategies at the 
level of the general population as well. It has not been established unequivocally whether 
the humoral and genetic markers used in the prediction of type 1 diabetes in first-degree 
relatives have a similar predictive value in the general population. Only a few prospective 
reports have been published describing the occurrence of disease-associated 
autoantibodies or their relation to genetic risk markers, and thus risk assessment 
strategies still remain to be established for non-familial type 1 diabetes.  
As in first-degree relatives, the present results and others support the view that the 
frequency of autoantibodies in the general population is considerably higher than that of 
the disease itself. The reported frequencies of antibodies vary widely (167, 317, 319), one 
reason probably being a true country-to-country variation and another methodological 
differences. As lower cut-off limits did not improve the diagnostic sensitivity of any 
autoantibody in the present series, higher cut-off levels should be used when wishing to 
minimize the false-positive rate. These data also illustrate the difficulty of defining the 
borderline positivity and of directly comparing the results of different studies, and 
emphasize the need for common international standards to be used in these autoantibody 
assays.  
Little is known about the associations between autoantibodies and HLA markers in the 
general population. Our present observation of a positive association between GADA and 
high risk DQB1 markers is in line with our findings in siblings, while conflicting results 
have been reported in patients with type 1 diabetes, in whom GADA have been related to 
DQB1 markers associated with a low, though increased disease risk (167, 169, 200). In 
our present series the HLA-DQB1 high risk markers were also related to the presence of 
multiple autoantibodies. On the other hand, none of the nine children with three or four 
antibody specificities had a high risk DQB1 genotype, although seven of them (78%) 
carried either the DQB1*0302 or the DQB1*02 risk allele. Surprisingly, three of these 
nine subjects even had a protective genotype. Accordingly, the ongoing beta-cell 
autoimmunity in these three subjects was probably initiated by powerful environmental 
factors and/or is related to genetic factors other than those residing in the HLA region. 
The natural course of humoral autoimmunity, i.e. changes in positivity and in the 
quantities of autoantibodies, has mainly been studied in first-degree relatives of patients 
with type 1 diabetes (253, 265, 278, 286). The present results show that all the individual 
markers of humoral islet autoimmunity may fluctuate during prospective follow-up in 75 
healthy schoolchildren as well. In the majority of cases the antibody status will remain 
stable, however, so that seroconversion to ICA negativity, for example, was relatively 
rare and usually associated with low titres and positivity for ICA only. 
Only a limited number of reports have been published on the relationships between 
autoantibodies and FPIR in the general population (284, 317). The present results indicate 
that a decreased FPIR is primarily associated with positivity for multiple antibodies, 
although the IAA-positive children among those with multiple antibodies had the lowest 
median FPIR. Our observations also confirm that humoral autoimmunity reflects 
impaired beta-cell function and probably an ongoing destructive process. Also, the 
genetic determinants of FPIR are poorly defined, and the few studies published have 
produced controversial results (308, 357, 358). The present study of healthy 
schoolchildren did not point to any relation between HLA-DQB1 risk alleles or 
genotypes and FPIR irrespective of the antibody status. These observations may reflect 
differences in the genetic background or in the disease process itself between siblings of 
children with type 1 diabetes and healthy unselected schoolchildren. Family members 
may carry additional susceptibility genes which may have an epistatic effect with HLA 
genes on the disease process, and therefore decreased FPIRs are found to be associated 
with HLA markers among siblings but not necessarily in the general population.  
Only four schoolchildren have so far progressed to type 1 diabetes, all of them having 
multiple antibodies in their serum at the time of the initial screening. An IVGTT was 
performed more than one year before the diagnosis in two of them, and both had a 
reduced FPIR. In contrast, the results demonstrate that at least in some individuals 
representing the general population, HLA-DQB1 risk markers are not indispensable for 
progression to overt type 1 diabetes, and the "protective" allele does not provide full 
protection against the disease. The lack of any apparent association between genetic risk 
markers and FPIR or progression to overt diabetes in the present series is intriguing. The 
number of children with a reduced FPIR and the number who presented with clinical 
disease are both low, however, which limits the interpretation of the data. On the other 
hand, we have previously observed a higher frequency of protective DQB1 alleles among 
children diagnosed with type 1 diabetes at an age older than 5 years than in those 
diagnosed at a younger age (359). This effect may contribute to the present results, since 
all the schoolchildren were older than 9 years when tested for their FPIR or diagnosed as 
having type 1 diabetes. 
Two recent studies have proposed a two-step screening strategy for the prediction of 
type 1 diabetes in the general population (317, 319). The first step should include 
screening for GADA and IA-2A, followed by screening for ICA and/or IAA as the 
second step. Such a strategy would have identified all the progressors in the present 
series. On the other hand, testing for IAA did not affect the sensitivity, whereas exclusion 
of ICA testing at the second step would have resulted in the loss of one progressor. 
Although autoantibodies were 100% sensitive in predicting type 1 diabetes, no screening 
strategy had a PPV exceeding 50%. Furthermore, the HLA-DQB1 risk markers even 
complicated the prediction, since the two progressors with a “protective” DQB1*0602 or 
*0603 allele would have been classified as subjects with a low risk of progression to type 
1 diabetes. These results demonstrate that extensive prospective studies on the 
characteristics of various predictive markers are needed before accurate risk assessment 
strategies can be established in the general population. The present data strongly support 76 
the use of combined screening for autoantibodies, whereas the value of current genetic 
risk markers for the prediction of type 1 diabetes in the general population may be 
challenged. 
6.4. Methodological aspects 
Although the present work provides a multitude of new data on the prevalence and 
predictive value of various markers in large series of unaffected siblings and 
schoolchildren there are some methodological aspects that should be considered when 
evaluating these results. The performance characteristics of the autoantibody assays have 
a critical impact on the detected frequency and predictive value of autoantibodies. The 
current method for the detection of ICA involves microscopic determination of 
immunofluorescence reflecting the binding of autoantibodies in sera to frozen sections of 
human pancreas (126). A substantial variability in this assay is unavoidable because of 
the use of different pancreatic specimens both between laboratories and within 
laboratories over time. Yearly serum exchanges to standardize ICA and a proficiency 
testing programme to monitor assay performance have been organised for several years 
by the Immunology of Diabetes Workshops (IDW) and supported by the Juvenile 
Diabetes Foundation (360-363), and the present laboratory has been a regular participant 
in these activities. Despite the excellent performance characteristics of our ICA assay, 
some samples with low titres may in fact be false positive and some ICA-negative 
samples may be false negative thereby affecting the reported frequency of ICA in the 
present populations. Furthermore, a minor proportion of the observed fluctuations in the 
ICA titre during the follow-up may result from pancreas variability. To overcome these 
problems and to assess the assay drift over time, high and low standards have been 
analysed regularly. It is obvious that these variability factors have only a minor effect on 
the present results, and the conclusions drawn are valid. 
The low sensitivity and PPV of IAA in siblings may partly be due to the fact that our 
IAA assay is not among the most sensitive. Hence an IAA assay with optimal sensitivity 
would probably result in somewhat better predictive characteristics than those observed 
in the present study of siblings. In addition, the assays for GADA, IAA and IA-2A suffer 
from the difficulty of defining the cut-off limits for antibody positivity, and the need for 
international standards for optimizing these assays should be emphasised. An 
international collaborative study has recently been organized to develop such standards 
for these autoantibody assays (364). To minimize the false positive and false negative 
rates for GADA and IA-2A in the present study, all samples with borderline results were 
repeated. 
Although the present series of siblings and schoolchildren are large, the number of 
those who progress to type 1 diabetes is still limited. This results in wide confidence 
intervals for the predictive estimates, especially for the schoolchild population and for the 
analysis of subgroups of siblings.  77 
6.5. Prospects for future research 
The present work was focused on the prediction of type 1 diabetes and the elucidation of 
the preclinical course of beta-cell autoimmunity. Although several major conclusions can 
be drawn from the present results and valuable data are provided to elucidate the complex 
pathogenesis underlying type 1 diabetes, future research in this area is warranted. 
Reasonable prediction is achieved with the current risk markers, but additional markers 
are needed to improve the current risk assessment both in siblings and in the general 
population. It is of interest whether autoantibodies to GLIMA (238) or those directed 
against an enzyme bile salt-dependent lipase (BSDL) (251) would provide the missing 
pieces in the puzzle of prediction. In addition to HLA markers, the value of other genetic 
susceptibility markers (e.g. insulin gene region polymorphism) for disease prediction also 
needs to be established. Furthermore, T-cell responses to beta-cell autoantigens may also 
have a role among the tools for predicting type 1 diabetes, although the problems related 
to the T-cell assay methodology need to be resolved first (173). Development and 
standardisation of the present autoantibody assays is also a prerequisite for improved 
prediction and worldwide applicability of the results. 
Further follow-up of the siblings included in the present study will show whether the 
autoimmunity detected in the current non-progressors ultimately leads to clinical 
presentation with type 1 diabetes. Therefore, the present analyses regarding the predictive 
characteristics of autoantibodies and HLA markers should be repeated, e.g. after 5 and 10 
years, to see if a long-term follow-up further improves the prediction in siblings. New 
prospective follow-up studies with frequent parallel measurements of IVGTTs, T-cell 
responses and autoantibodies in unselected populations of first-degree relatives are still 
needed to resolve the pathogenetic course of familial preclinical type 1 diabetes.  
Continuous prospective follow-up of the present population of schoolchildren will also 
provide more reliable risk estimates after 5 to 10 years. Due to the controversial 
observation regarding the value of HLA-DQB1 markers for the prediction of type 1 
diabetes in the present population, DQB1-typing is currently being performed on all 
subjects. The determination of other genetic susceptibility markers in this population 
would also be of interest. Subsequent analyses should thereafter cast further light on the 
relationships between genetic and other markers in the general population. More 
prospective studies on large series of individuals representing the general population are 
urgently needed to establish definitive predictive strategies for background populations. 
In the Finnish DIPP study all newborn children are being enrolled for genetic screening 
and the high-risk individuals are subsequently observed for beta-cell autoimmunity and 
progression to type 1 diabetes. That study is expected to provide a lot of new information 
on the interactions between genetic and environmental factors and the course of beta-cell 
autoimmunity in the general population.  7. Conclusions 
The following conclusions can be drawn from the present results: 
 
1.  All four islet antibody specificities are useful markers for estimating the risk of 
progression to type 1 diabetes in siblings initially tested at or close to the 
diagnosis of the first affected child in the family, ICA having the highest 
sensitivity and IA-2A the highest PPV. The risk of progression to type 1 diabetes 
is related to the number of autoantibodies, and the presence of multiple 
antibodies is highly predictive of future development of type 1 diabetes in 
siblings. 
 
2.  Autoantibodies are closely associated with high-risk genetic markers in siblings.  
 
3.  The combination of humoral and genetic markers increases the accuracy of the 
prediction, but also results in reduced sensitivity. Accordingly, autoantibodies 
alone rather than in combination with genetic markers are recommended for 
first-line screening in siblings. However, when the most susceptible subjects are 
to be identified, e.g. for intervention trials, high-risk genetic markers in 
combination with autoantibodies offer an excellent tool for identifying them.  
 
4.  Accurate assessment of the risk of type 1 diabetes in siblings is a complicated 
matter, as not all of those with a broad initial humoral autoimmune response 
and/or high risk HLA markers progress to clinical disease, while some siblings 
with a low genetic risk and minor initial signs of humoral autoimmunity may 
present with the disease. 
 
5.  Siblings who progress to clinical type 1 diabetes are characterised by the high-
risk HLA-DQB1 markers, low FPIR and humoral autoimmunity against multiple 
targets in pancreatic beta cells. The course of the preclinical autoimmune 
process is nevertheless highly heterogeneous both in the rate and pattern of 
humoral autoimmunity.  
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6.  The autoimmune process resulting in clinical manifestation of type 1 diabetes in 
siblings could not be unambiguously distinguished from autoimmunity that does 
not lead to clinical disease over a long follow-up period.  
 
7.  Autoantibodies are associated with a reduced FPIR and progression to type 1 
diabetes, and partially also with HLA-DQB1 risk markers in a series of 
schoolchildren representing the general population. However, the DQB1 alleles 
conferring decreased disease susceptibility do not provide complete protection 
from strong humoral beta-cell autoimmunity, deterioration in beta-cell function 
or from progression to overt type 1 diabetes. 
 
8.  Combined screening for autoantibodies is recommended for assessing the risk of 
progression to type 1 diabetes in schoolchildren, whereas the value of current 
genetic risk markers in such populations may be challenged.8. References 
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